Peeters Protides of the Biological Fluids

Proceedings of the Thirty-First Colloquium, 1983
1. Auflage 2014
ISBN: 978-1-4832-7965-7
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, Band Volume 31, 1144 Seiten, Web PDF

Reihe: Protides of the Biological Fluids

Protides of the Biological Fluids: Metal Binding Proteins, Tumor Markers, Monoclonal Antibodies covers the proceedings of the 31st Colloquium by the same title, held in Brussels, Belgium in 1983. This work is composed of three sections encompassing 245 chapters. The first section describes first the structure, physiological function, and physiopathology of metal binding proteins. This section also considers the metal binding mechanism and a series of iron binding and copper binding proteins, as well as hemopexin proteins. The second section is concerned with the physiopathology, screening, monitoring, tumor localization, and biomarkers of tumor. This section also explores the field of immunohistochemistry of biomarkers for tumor monitoring. The third section discusses drug targeting, immunohistochemistry, the identification of lymphocytes and other antigens. Considerable chapters are devoted to clinical assays of monoclonal antibodies. This book will prove useful to oncologists, protein scientists, clinicians, and researchers.

Autoren/Hrsg.

Peeters, H.

Inhaltsverzeichnis

1;Front Cover;1
2;Protides of the Biological Fluids;4
3;Copyright Page;5
4;Table of Contents;6
5;PREFACE;6
6;ACKNOWLEDGEMENTS;6
7;PART I:
THE TWELFTH ARNE TISELIUS MEMORIAL LECTURE;34
8;Chapter 1. Association Between HLA and Diseases: Biological and Clinical Relevance;36
8.1;ABSTRACT;36
8.2;KEYWORDS;36
8.3;I. INTRODUCTION;36
8.4;II. THE HLA SUPERGENE;36
8.5;III. METHODOLOGY;37
8.6;IV. ANKYLOSING SPONDYLITIS (AS);39
8.7;V. COELIAC DISEASE (CD);40
8.8;REFERENCES;43
9;SECTION A:
Metal Binding Proteins;46
9.1;..1.
Metal Binding Mechanism;48
9.1.1;CHAPTER
2. METAL BINDING TO SERUM PROTEINS;48
9.1.1.1;ABSTRACT;48
9.1.1.2;KEYWORDS;48
9.1.1.3;INTRODUCTION;48
9.1.1.4;RESULTS AND DISCUSSION;49
9.1.1.5;ACKNOWLEDGEMENT;51
9.1.1.6;REFERENCES;51
9.1.2;CHAPTER 3. INTERACTIONS OF PREGNANCY ASSOCIATED PLASMA PROTEIN-A AND a2 MACROGLOBULIN ON METAL CHELATE
AFFINITY CHROMATOGRAPHY;52
9.1.2.1;ABSTRACT;52
9.1.2.2;KEYWORDS;52
9.1.2.3;INTRODUCTION;52
9.1.2.4;MATERIALS AND METHODS;52
9.1.2.5;RESULTS AND DISCUSSION;53
9.1.2.6;ACKNOWLEDGEMENTS;55
9.1.2.7;REFERENCES;55
9.1.3;CHAPTER 4. INTERACTIONOF THE HISTIDINE-RICH GLYCOPROTEINOF SERUM WITH METALS
AND PLASMIN;56
9.1.3.1;ABSTRACT;56
9.1.3.2;KEYWORDS;56
9.1.3.3;INTROOOCTION;56
9.1.3.4;MATERIALS AND
METHODS;56
9.1.3.5;RESULTS AND
DISCUSSION;57
9.1.3.6;ACKNOWLEDGEMENTS;59
9.1.3.7;REFERENCES;59
9.1.4;CHAPTER 5. BINDING OF CALCIUM TO INTRINSIC FACTOR AND TO THE ALPHA SUBUNIT OF
ITS RECEPTOR;60
9.1.4.1;ABSTRACT;60
9.1.4.2;KEYWORDS;60
9.1.4.3;INTRODUCTION;60
9.1.4.4;MATERIALS AND METHODS;61
9.1.4.5;RESULTS;61
9.1.4.6;DISCUSSION;63
9.1.4.7;ACKNOWLEDGEMENTS;63
9.1.4.8;REFERENCES;63
9.1.5;CHAPTER 6. SPECIFICITY OF METAL BINDING TO
SERUM THYMIC FACTOR (FTS);64
9.1.5.1;ABSTRACT;64
9.1.5.2;KEYWORDS;64
9.1.5.3;INTRODUCTION;64
9.1.5.4;MATERIALS and METHODS;65
9.1.5.5;RESULTS and DISCUSSION;65
9.1.5.6;ACKNOWLEDGEMENT;67
9.1.5.7;REFERENCES;67
9.1.6;CHAPTER 7. HYDROGEN PEROXIDE INVOLVEMENT IN THE MECHANISM OF ACTION OF CYTOCHROME
c OXIDASE;68
9.1.6.1;CATALASE ACTIVITY.;68
9.1.6.2;PEROXIDASE ACTIVITY;70
9.1.6.3;DISCUSSION.;71
9.1.6.4;REFERENCES;71
9.1.7;CHAPTER 8. ZINC AND IRON ABSORPTION IN ENDOTOXIN
PRETREATED RATS;72
9.1.7.1;ABSTRACT;72
9.1.7.2;KEYWORDS;72
9.1.7.3;INTRODUCTION;72
9.1.7.4;METHODS;72
9.1.7.5;RESULTS AND DISCUSSION;73
9.1.7.6;ACKNOWLEDGEMENT;75
9.1.7.7;REFERENCES;75
9.1.8;CHAPTER 9. A SENSITIVE MICROMETHOD FOR THE STUDY OF IRON UPTAKE BY MITOGEN'STIMULATED HUMAN BLOOD MONONUCLEAR
LEUKOCYTES;76
9.1.8.1;ABSTRACT;76
9.1.8.2;INTRODUCTION;76
9.1.8.3;MATERIALS AND METHODS;76
9.1.8.4;RESULTS AND DISCUSSION;77
9.1.8.5;ACKNOWLEDGMENT;79
9.1.8.6;REFERENCES;79
9.1.9;CHAPTER 10. IRON-DEFICIENCY ANAEMIA MODIFIES BRAIN FUNCTION VIA DOPAMINE
RECEPTOR SUBSENSITIVITY;80
9.1.9.1;ABSTRACT;80
9.1.9.2;KEYWORDS;80
9.1.9.3;INTRODUCTION;80
9.1.9.4;RESULTS AND DISCUSSION;81
9.1.9.5;REFERENCES;84
9.2;..2, Iron Binding Proteins;86
9.2.1;A.2.1. Transferrin;86
9.2.1.1;CHAPTER 11. THE MOLECULAR BASIS OF FERROKINETICS: THE EXPLANATION OF
THE FLETCHER'HUEHNS PHENOMENON;86
9.2.1.1.1;ABSTRACT;86
9.2.1.1.2;KEYWORDS;86
9.2.1.1.3;INTRODUCTION;86
9.2.1.1.4;MATERIALS AND METHODS;87
9.2.1.1.5;RESULTS;88
9.2.1.1.6;DISCUSSION;89
9.2.1.1.7;ACKNOWLEDGEMENT;90
9.2.1.1.8;REFERENCES;90
9.2.1.2;CHAPTER 12. THE DISCOVERYOF TRANSFERRIN IN
INVERTEBRATES;92
9.2.1.2.1;ABSTRACT;92
9.2.1.2.2;KEYWORDS;92
9.2.1.2.3;INTRODUCTION;92
9.2.1.2.4;MATERIALS AND METHODS;92
9.2.1.2.5;RESULTS;93
9.2.1.2.6;CONCLUSIONS;93
9.2.1.2.7;ACKNOWLEDGMENT;93
9.2.1.2.8;REFERENCES;93
9.2.1.3;CHAPTER 13. CROSSED IMMUNOAFFINITY ELECTROPHORESIS OF HUMAN TRANSFERRIN IN NORMAL AND
CIRRHOTIC SERA;96
9.2.1.3.1;ABSTRACT;96
9.2.1.3.2;KEYWORDS;96
9.2.1.3.3;INTRODUCTION;96
9.2.1.3.4;MATERIAL AND METHODS;96
9.2.1.3.5;RESULTS;97
9.2.1.3.6;DISCUSSION;100
9.2.1.3.7;ACKNOWLEDGEMENTS;100
9.2.1.3.8;REFERENCES;100
9.2.1.4;CHAPTER 14. HETEROGENEITY OF HUMAN
TRANSFERRINS;102
9.2.1.4.1;ABSTRACT;102
9.2.1.4.2;KEYWORDS;102
9.2.1.4.3;INTRODUCTION;102
9.2.1.4.4;METHODS AND MATERIALS;102
9.2.1.4.5;RESULTS;103
9.2.1.4.6;DISCUSSION;104
9.2.1.4.7;REFERENCES;104
9.2.1.5;CHAPTER 15. NO FUNCTIONAL DIFFERENCE OF THE TWO IRON-BINDING SITES OF HUMAN TRANSFERRIN IN VITRO AND IN
VIVO;106
9.2.1.5.1;ABSTRACT;106
9.2.1.5.2;KEYWORDS;106
9.2.1.5.3;INTRODUCTION;106
9.2.1.5.4;MATERIALS AND METHODS;107
9.2.1.5.5;RESULTS;107
9.2.1.5.6;DISCUSSION;108
9.2.1.5.7;REFERENCES;108
9.2.1.6;CHAPTER 16. TRANSFERRIN PROTEIN AND IRON UPTAKE BY CULTURED MAMMALIAN
CELLS;110
9.2.1.6.1;ABSTRACT;110
9.2.1.6.2;KEY WORDS;110
9.2.1.6.3;INTRODUCTION;110
9.2.1.6.4;RESULTS;111
9.2.1.6.5;DISCUSSION;112
9.2.1.6.6;REFERENCES;113
9.2.1.7;CHAPTER 17. INTERACTION BETWEEN TRANSFERRIN
AND TUMOR CELL RECEPTOR;114
9.2.1.7.1;ABSTRACT;114
9.2.1.7.2;KEYWORDS;114
9.2.1.7.3;INTRODUCTION;114
9.2.1.7.4;MATERIALS AND METHODS;115
9.2.1.7.5;RESULTS AND DISCUSSION;116
9.2.1.7.6;REFERENCES;119
9.2.1.8;CHAPTER 18. REDOX REACTIONS IN HEPATOCYTE IRON
UPTAKE;120
9.2.1.8.1;MATERIALS AND METHODS;120
9.2.1.8.2;RESULTS AND DISCUSSION;120
9.2.1.8.3;REFERENCES;123
9.2.1.9;CHAPTER 19. TRANSFERR IN AS A DONOR OF IRON TO
RAT LIVER MITOCHONDRIA … EFFECT OF PYROPHOSPHATE;124
9.2.1.9.1;MATERIALS AND METHODS;124
9.2.1.9.2;RESULTS AND DISCUSSION;125
9.2.1.9.3;REFERENCES;127
9.2.1.10;CHAPTER 20. THE KINETICS OF DUODENAL MUCOSA IRON UPTAKE IN THE DEVELOPING
GUINEA PIG;128
9.2.1.10.1;ABSTRACT;128
9.2.1.10.2;KEY WORDS;128
9.2.1.10.3;INTRODUCTION;128
9.2.1.10.4;METHODS;129
9.2.1.10.5;RESULTS;129
9.2.1.10.6;DISCUSSION;130
9.2.1.10.7;REFERENCES;131
9.2.1.11;CHAPTER 21. TRANSFERRIN PROTEIN AND IRON UPTAKE BY
LIVER PARENCHYMAL CELLS;132
9.2.1.11.1;ABSTRACT;132
9.2.1.11.2;KEY WORDS;132
9.2.1.11.3;INTRODUCTION;132
9.2.1.11.4;MATERIAL AND METHODS;133
9.2.1.11.5;RESULTS;133
9.2.1.11.6;DISCUSSION;135
9.2.1.11.7;REFERENCES;135
9.2.1.12;CHAPTER
22. INTESTINAL TRANSFERRIN;136
9.2.1.12.1;ABSTRACT;136
9.2.1.12.2;KEYWORDS;136
9.2.1.12.3;INTRODUCTION;136
9.2.1.12.4;METHODS;137
9.2.1.12.5;RESULTS;138
9.2.1.12.6;DISCUSSION;139
9.2.1.12.7;ACKNOWLEDGEMENTS;139
9.2.1.12.8;REFERENCES;139
9.2.1.13;CHAPTER 23. UPTAKE OF 59Fe- 125I- TRANSFERRIN BY K-562
CELLS;140
9.2.1.13.1;MATERIALS AND METHODS;140
9.2.1.13.2;RESULTS AND DISCUSSION;140
9.2.1.13.3;REFERENCES;142
9.2.1.14;CHAPTER 24. ISOELECTRIC FOCUSING OF INHERITED TRANSFERRIN VARIANTS WITH
IMMOBILIZED pH GRADIENTS;144
9.2.1.14.1;ABSTRACT;144
9.2.1.14.2;INTRODUCTION;144
9.2.1.14.3;RESULTS;145
9.2.1.14.4;REFERENCES;147
9.2.1.15;CHAPTER 25. AN ELISA TECHNIQUE FOR MEASUREMENT OF TRANSFERRIN GLYCO-VARIANTS IN BODY FLUIDS USING LECTINS BOUND TO A SOLID
PHASE;148
9.2.1.15.1;ABSTRACT;148
9.2.1.15.2;KEYWORDS;148
9.2.1.15.3;INTRODUCTION;148
9.2.1.15.4;RESULTS;150
9.2.1.15.5;CONCLUSIONS;150
9.2.1.15.6;REFERENCES;151
9.2.1.16;CHAPTER 26. DOES IRON-TRANSFERRIN SATURATION INFLUENCE THE IMMUNOTURBIDIMETRIC DETERMINATION OF HUMAN SERUM
TRANSFERRIN?;152
9.2.1.16.1;ABSTRACT;152
9.2.1.16.2;INTRODUCTION;152
9.2.1.16.3;MATERIAL AND METHODS;152
9.2.1.16.4;RESULTS;153
9.2.1.16.5;STATISTICAL EVALUATION;154
9.2.1.16.6;DISCUSSION;155
9.2.1.16.7;REFERENCES;155
9.2.2;A .2.2. Lactotransferrin;156
9.2.2.1;CHAPTER 27. THE PRESENT STATE OF THE HUMAN
LACTOTRANSFERRIN SEQUENCE;156
9.2.2.1.1;ABSTRACT;156
9.2.2.1.2;KEYWORDS;156
9.2.2.1.3;INTRODUCTION;156
9.2.2.1.4;RESULTS;156
9.2.2.1.5;CONCLUSION;160
9.2.2.1.6;REFERENCES;160
9.2.2.2;CHAPTER 28. LACTOFERRIN STIMULATES THE PRODUCTION OF ''LEUKOCYTE MIGRATION INHIBITORY FACTOR'' (LIF)
BY MONONUCLEAR LEUKOCYTES;162
9.2.2.2.1;ABSTRACT;162
9.2.2.2.2;INTRODUCTION;162
9.2.2.2.3;MATERIALS AND METHODS;162
9.2.2.2.4;DISCUSSION;164
9.2.2.2.5;ACKNOWLEDGEMENTS;165
9.2.2.2.6;REFERENCES;165
9.2.2.3;CHAPTER 29. LACTOFERRIN UPTAKE BY THE RETICULOENDOTHELIAL SYSTEM OF THE MOUSE LIVER;166
9.2.2.3.1;ABSTRACT;166
9.2.2.3.2;KEYWORDS;166
9.2.2.3.3;INTRODUCTION;166
9.2.2.3.4;MATERIALS AND METHODS;166
9.2.2.3.5;RESULTS;167
9.2.2.3.6;DISCUSSION;169
9.2.2.3.7;ACKNOWLEDGEMENTS;169
9.2.2.3.8;REFERENCES;169
9.2.2.4;CHAPTER 30. COMPARISON OF THE INTERACTION OF LACTOFERRIN WITH HEPATOCYTES,
LYMPHOCYTES AND MONOCYTES;170
9.2.2.4.1;ABSTRACT;170
9.2.2.4.2;KEYWORDS;170
9.2.2.4.3;INTRGDUCTIGN;170
9.2.2.4.4;MATERIALS AND METHGOS;170
9.2.2.4.5;RESULTS;171
9.2.2.4.6;DISCUSSION;171
9.2.2.4.7;REFERENCES;173
9.2.2.5;CHAPTER 31. COMPARATIVE STUDY OF THE IRON BINDING SITES OF TRANSFERRINS: DEMONSTRATION OF THE NON-IDENTITY OF THE TWO SITES OF HUMAN
LA CTOTRANSFERRIN;174
9.2.2.5.1;KEYWORDS;174
9.2.2.5.2;BINDING OF V02+ AS A PROBE OF THE ENVIRONMENT OF THE METAL BINDING SITE;174
9.2.2.5.3;STABILITY OF THE IRON BINDING SITES TOWARDS PROTONATION;175
9.2.2.5.4;HISTIDINE AS LIGANDS AT THE IRON-BINDING SITES;175
9.2.2.5.5;CONCLUSION;175
9.2.2.5.6;ACKNOWLEDGEMENTS;176
9.2.2.5.7;REFERENCES;176
9.2.2.6;CHAPTER 32. LACTOFERRIN BINDING TO PERIPHERAL
HUMAN LEUKOCYTES;178
9.2.2.6.1;INTRODUCTION;178
9.2.2.6.2;MATERIALS AND METHODS;178
9.2.2.6.3;RESULTS AND DISCUSSION;179
9.2.2.6.4;ACKNOWLEDGEMENTS;181
9.2.2.6.5;REFERENCES;181
9.2.2.7;CHAPTER 33. LACTOFERRINAND TRANSFERRIN LEVELS IN THE SEMINAL PLASMA OF
INFERTILE MEN;182
9.2.2.7.1;ABSTRACT;182
9.2.2.7.2;KEYWORDS;182
9.2.2.7.3;INTRODUCTION;182
9.2.2.7.4;MATERIAL AND METHODS;183
9.2.2.7.5;RESULTS;183
9.2.2.7.6;DISCUSSION;184
9.2.2.7.7;ACKNOWLEDGEMENTS;186
9.2.2.7.8;REFERENCES;186
9.2.3;A.2.3. Ovotransferrin;188
9.2.3.1;CHAPTER
34. BINDING SITE STUDIES OF OVOTRANSFERRIN BY UV AND NMR SPECTROSCOPIES;188
9.2.3.1.1;ABSTRACT;188
9.2.3.1.2;KEYWORDS;188
9.2.3.1.3;INTRODUCTION;188
9.2.3.1.4;MATERIALS AND METHODS;188
9.2.3.1.5;RESULTS AND DISCUSSION;190
9.2.3.1.6;ACKNOWLEDGEMENTS;191
9.2.3.1.7;REFERENCES;191
9.2.4;A.2.4. Ferritin;192
9.2.4.1;CHAPTER 35. INTRACELLULAR IRON METABOLISM
REVISITED;192
9.2.4.1.1;ABSTRACT;192
9.2.4.1.2;KEY WORDS;192
9.2.4.1.3;INTRODUCTION;192
9.2.4.1.4;CURRENT CONCEPTS OF FERRITIN IRON MOBILISATION;192
9.2.4.1.5;FLAVIN-MEDIATED FERRITIN IRON MOBILISATION FOR HAEM
SYNTHESIS;193
9.2.4.1.6;FERRITIN IRON MOBILISATION AS A FUNCTION OF pH;194
9.2.4.1.7;CONCLUSIONS;195
9.2.4.1.8;ACKNOWLEDGEMENTS;195
9.2.4.1.9;REFERENCES;195
9.2.4.2;CHAPTER
36. THE METABOLISM OF PLASMA FERRITIN;198
9.2.4.2.1;ABSTRACT;198
9.2.4.2.2;KEYWORDS;198
9.2.4.2.3;INTRODUCTION;198
9.2.4.2.4;RESULTS AND DISCUSSION;198
9.2.4.2.5;ACKNOWLEDGEMENT;202
9.2.4.2.6;REFERENCES;202
9.2.4.3;CHAPTER 37. AMINO ACID SEQUENCE STUDIES ON
HUMAN APOFERRITINS;204
9.2.4.3.1;ABSTRACT;204
9.2.4.3.2;KEY WORDS;204
9.2.4.3.3;INTRODUCTION;204
9.2.4.3.4;METHODS;205
9.2.4.3.5;RESULTS;205
9.2.4.3.6;DISCUSSION;208
9.2.4.3.7;ACKNOWLEDGEMENTS;209
9.2.4.3.8;REFERENCES;209
9.2.4.4;CHAPTER 38. FERRITIN STRUCTURE
AND FUNCTION;210
9.2.4.4.1;ABSTRACT;210
9.2.4.4.2;KEYWORDS;210
9.2.4.4.3;INTRODUCTION;210
9.2.4.4.4;STRUCTURE OF THE APOFERRITIN SUBUNIT;210
9.2.4.4.5;ASSEMBLY OF THE APOFERRITIN SHELL;212
9.2.4.4.6;PROPERTIES OF THE APOFERRITIN SHELL;213
9.2.4.4.7;SEQUENCE HOMOLOGIES WITH OTHER FERRITINS;215
9.2.4.4.8;SUMMARY;215
9.2.4.4.9;ACKNOWLEDGEMENT;215
9.2.4.4.10;REFERENCES;215
9.2.4.5;CHAPTER
39. FERRITIN AND METAL ........;216
9.2.4.5.1;References;219
9.2.4.6;CHAPTER 40. ANALYSIS OF VARIOUS ISOFERRITINS
WITH MONOCLONAL ANTIBODIES;220
9.2.4.6.1;ABSTRACT;220
9.2.4.6.2;KEYWORDS;220
9.2.4.6.3;INTRODUCTION;220
9.2.4.6.4;MATERIALS AND METHODS;220
9.2.4.6.5;RESULTS;221
9.2.4.6.6;DISCUSSION;223
9.2.4.6.7;ACKNOWLEDGEMENT;223
9.2.4.6.8;REFERENCES;223
9.2.4.7;CHAPTER 41. POSSIBLE CHANGES IN THE ISOFERRITIN PROFILE DURING INFANCY AND
CHILDHOOD;224
9.2.4.7.1;INTRODUCTION;224
9.2.4.7.2;MATERIALS AND METHODS;224
9.2.4.7.3;RESULTS;225
9.2.4.7.4;DISCUSSION;227
9.2.4.7.5;REFERENCES;227
9.2.4.8;CHAPTER 42. INCREASED URINARY EXCRETION OF FERRITIN IN SUBJECTS WITH MODERATE
PROTEINURIA;228
9.2.4.8.1;ABSTRACT;228
9.2.4.8.2;KEYWORDS;228
9.2.4.8.3;INTRODUCTION;228
9.2.4.8.4;MATERIALS AND
METHODS;228
9.2.4.8.5;RESULTS;229
9.2.4.8.6;REFERENCES;231
9.2.4.9;CHAPTER 43. THE ISOFERRITIN COMPOSITION OF RAT LIVER DURING BLEEDING INDUCED
CATABOLISM OF LIVER FERRITIN;232
9.2.4.9.1;ABSTRACT;232
9.2.4.9.2;KEYWORDS;232
9.2.4.9.3;INTRODUCTION;232
9.2.4.9.4;METHODS;232
9.2.4.9.5;RESULTS;233
9.2.4.9.6;DISCUSSION;234
9.2.4.9.7;REFERENCES;235
9.2.4.10;CHAPTER 44. INFLUENCE OF HEAT-TREATMENT ON
RABBIT LIVER-FERRITIN;236
9.2.4.10.1;ABSTRACT;236
9.2.4.10.2;KEYWORDS;236
9.2.4.10.3;INTRODUCTION;236
9.2.4.10.4;MATERIALS AND METHODS;236
9.2.4.10.5;RESULTS;237
9.2.4.10.6;DISCUSSION;239
9.2.4.10.7;ACKNOWLEDGEMENTS;239
9.2.4.10.8;REFERENCES;239
9.2.4.11;CHAPTER 45. IRON MOBILIZATION FROM CULTURED RAT MACROPHAGES LOADED WITH
59Fe LABELLED ERYTHROBLASTS;240
9.2.4.11.1;ABSTRACT;240
9.2.4.11.2;KEY WORDS;240
9.2.4.11.3;INTRODUCTION;240
9.2.4.11.4;MATERIAL AND METHODS;241
9.2.4.11.5;RESULTS;241
9.2.4.11.6;DISCUSSION;243
9.2.4.11.7;REFERENCES;243
9.2.4.12;CHAPTER 46. SERUM FERRITIN LEVEL IN
HEMODIALYSIS PATIENTS;244
9.2.4.12.1;ABSTRACT;244
9.2.4.12.2;KEYWORDS;244
9.2.4.12.3;INTRODUCTION;244
9.2.4.12.4;MATERIAL AND METHODS;244
9.2.4.12.5;RESULTS;245
9.2.4.12.6;REFERENCES;247
9.2.5;A.2.5. Hemopexin and others;248
9.2.5.1;Chapter 47. STRUCTURALSTUDIES OF HUMAN
HEMOPEXIN;248
9.2.5.1.1;ABSTRACT;248
9.2.5.1.2;KEYWORDS;248
9.2.5.1.3;INTRODUCTION;248
9.2.5.1.4;MATERIALS AND METHODS;249
9.2.5.1.5;RESULTS AND DISCUSSION;249
9.2.5.1.6;REFERENCES;251
9.2.5.2;CHAPTER 48. CLEAVAGE OF RABBIT HEMOPEXIN BY PLASMIN AND ISOLATION OF TWO
GLYCOPEPTIDES;252
9.2.5.2.1;ABSTRACT;252
9.2.5.2.2;KEYWORDS;252
9.2.5.2.3;INTRODUCTION;252
9.2.5.2.4;MATERIALS AND
METHODS;253
9.2.5.2.5;RESULTS AND DISCUSSION;253
9.2.5.2.6;ACKNOWLEIXIMINTS;256
9.2.5.2.7;References;257
9.2.5.3;CHAPTER 49. PURIFICATION OF HUMAN HAEMOPEXIN BY AFFINITY CHROMATOGRAPHY USING IMMOBILIZED CIBACRON BLUE F3GA AND CONCANAVALIN
A;258
9.2.5.3.1;ABSTRACT;258
9.2.5.3.2;KEY WORDS;258
9.2.5.3.3;INTRODUCTION;258
9.2.5.3.4;EXPERIMENTAL;259
9.2.5.3.5;RESULTS AND DISCUSSION;259
9.2.5.3.6;ACKNOWLEDGEMENTS;261
9.2.5.3.7;REFERENCES;261
9.2.5.4;CHAPTER 50. PURIFICATION OF THE PORCINE DUODENAL HAEM RECEPTOR USING A NEW AFFINITY CHROMATOGRAPHIC
MEDIUM;262
9.2.5.4.1;ABSTRACT;262
9.2.5.4.2;KEYWORDS;262
9.2.5.4.3;INTRODUCTION;262
9.2.5.4.4;MATERIALS AND METHODS;262
9.2.5.4.5;RESULTS AND DISCUSSION;263
9.2.5.4.6;ACKNOWLEDGEMENTS;265
9.2.5.4.7;REFERENCES;265
9.2.5.5;CHAPTER 51. UPTAKE AND RELEASEOF LABELLED FERRIOXAMINE AND DESFERRIOXAMINE DERIVATIVES BY CULTURED HEPATOCYTES
AND MACROPHAGES;266
9.2.5.5.1;ABSTRACT;266
9.2.5.5.2;KEY WORDS;266
9.2.5.5.3;INTRODUCTION;266
9.2.5.5.4;MATERIAL AND METHODS;267
9.2.5.5.5;RESULTS;267
9.2.5.5.6;DISCUSSION;269
9.2.5.5.7;REFERENCES;269
9.2.5.6;CHAPTER 52. FLUORIMETRIC AND KINETIC CHARACTERISTICS OF ERYTHROCYTE BOVINE CARBONIC
ANHYDRASES;270
9.2.5.6.1;ABSTRACTS;270
9.2.5.6.2;KEYWORDS;270
9.2.5.6.3;INTRODUCTION;270
9.2.5.6.4;MATERIAL AND METHODS;271
9.2.5.6.5;RESULTS;272
9.2.5.6.6;CONCLUSION;273
9.2.5.6.7;ACKNOWLEDGEMENT;273
9.2.5.6.8;REFERENCES;273
9.3;..3. Copper Binding Proteins;276
9.3.1;CHAPTER 53. THE DOMAIN STRUCTURE OF THE
HUMAN CERULOPLASMIN MOLECULE;276
9.3.1.1;ABSTRACT;276
9.3.1.2;KEYWORDS;276
9.3.1.3;INTRODUCTION;276
9.3.1.4;MATERIALS AND METHODS;277
9.3.1.5;RESULTS AND DISCUSSION;277
9.3.1.6;ACKNOWLEDGEMENTS;281
9.3.1.7;REFERENCES;281
9.3.2;CHAPTER 54. COPPER LOADED FETAL GUINEA PIG „ A
MODEL OF WILSON'S DISEASE?;282
9.3.2.1;ABSTRACT;282
9.3.2.2;KEY WORDS;282
9.3.2.3;INTRODUCTION;282
9.3.2.4;MATERIAL AND METHODS;283
9.3.2.5;RESULTS;283
9.3.2.6;DISCUSSION;284
9.3.2.7;REFERENCES;285
10;SECTION .: Tumour Markers;286
10.1;B.1. Overviews;288
10.1.1;CHAPTER 55. SUCCESSFUL USES OF TUMOUR MARKERS
IN MAN;288
10.1.1.1;ABSTRACT;288
10.1.1.2;KEYWORDS;288
10.1.1.3;INTRODUCTION;288
10.1.1.4;NATURAL HISTORY;289
10.1.1.5;DIAGNOSIS - EARLY;290
10.1.1.6;DIAGNOSIS - COMPASSIONATE;291
10.1.1.7;DIAGNOSIS - DIFFICULT - WHAT?;291
10.1.1.8;DIAGNOSIS - DIFFICULT - WHERE?;291
10.1.1.9;MONITORING - RESIDUAL TUMOUR;292
10.1.1.10;MONITORING - EARLY DETECTION OF RECURRENCE;292
10.1.1.11;MONITORING - RESPONSE TO TREATMENT;292
10.1.1.12;THERAPEUTIC TARGET;292
10.1.1.13;ACKNOWLEDGEMENT;294
10.1.1.14;REFERENCES;294
10.1.2;CHAPTER 56. ONCODEVELOPMENTAL GENE EXPRESSION: RELEVANCE TO CURRENT VIEWS ON
CANCER;296
10.1.2.1;ABSTRACT;296
10.1.2.2;Introduction;296
10.1.2.3;Current
Status;296
10.1.2.4;History
of conceptual views of cancer etiology;298
10.1.2.5;Oncogenes;299
10.1.2.6;Neoplastic
progression;299
10.1.2.7;Conclusions;300
10.1.2.8;ACKNOWLEDGEMENT;301
10.1.2.9;REFERENCES;301
10.1.3;CHAPTER
57. NATIONAL CANCER INSTITUTE SERUMIMMUNODIAGNOSTIC BANK AT MAYOCLINIC „ 10 YEARS EXPERIENCE;302
10.1.3.1;ABSTRACT;302
10.1.3.2;KEYWORDS;302
10.1.3.3;INTRODUCTION;302
10.1.3.4;GOALS AND HISTORICAL BACKGROUND;303
10.1.3.5;PROTOCOL & PROCEDURE;303
10.1.3.6;PROGRESS REPORT AND RESULTS;304
10.1.3.7;CONCLUDING REMARK;305
10.1.3.8;REFERENCES;306
10.1.4;CHAPTER 58. PREVALENCE OF TRANSFORMATION- ENHANCING ACTIVITY IN THE PLASMA OF CANCER
PATIENTS;308
10.1.4.1;ABSTRACT;308
10.1.4.2;KEY WORDS;308
10.1.4.3;INTRODUCTION;308
10.1.4.4;MATERIALS AND METHODS;309
10.1.4.5;RESULTS;309
10.1.4.6;DISCUSSION;312
10.1.4.7;ACKNOWLEDGMENTS;313
10.1.4.8;REFERENCES;313
10.1.5;CHAPTER
59. METHODS FOR SELECTION OF OPTIMALCOMBINATIONS IN MULTIPLE TUMORASSAY;314
10.1.5.1;INTRODUCTION;314
10.1.5.2;SENSITIVITY AT DEFINED SPECIFICITY;314
10.1.5.3;EVALUATION OF SENSITIVITIES ON A POCKET COMPUTER;315
10.1.5.4;CONCLUSIONS;316
10.2;..2. Tumour Localization in vivo;318
10.2.1;CHAPTER 60. COMPUTER ANALYSIS OF ANTIBODY
SCANS;318
10.2.1.1;ABSTRACT;318
10.2.1.2;KEYWORDS;318
10.2.1.3;INTRODUCTION;318
10.2.1.4;SUBTRACTION METHODS;318
10.2.1.5;SCAN RESULTS;320
10.2.1.6;CONCLUSIONS;320
10.2.1.7;ACKNOWLEDGEMENTS;321
10.2.1.8;REFERENCES;321
10.2.2;CHAPTER 61. INDIUM CHELATES FOR THE
RADIOIMMUNODETECTION OF TUMOURS;322
10.2.2.1;ABSTRACT;322
10.2.2.2;KEYWORDS;322
10.2.2.3;INTRODUCTION;322
10.2.2.4;METHODS;323
10.2.2.5;PATIENTS;323
10.2.2.6;RESULTS;323
10.2.2.7;CONCLUSIONS;325
10.2.2.8;ACKNOWLEDGEMENTS;325
10.2.2.9;REFERENCES;325
10.2.3;CHAPTER 62. RADIOIMMUNODETECTION OF
ENDOCRINE TUMOURS;326
10.2.3.1;ABSTRACT;326
10.2.3.2;KEYWORDS;326
10.2.3.3;INTRODUCTION;326
10.2.3.4;METHODS;327
10.2.3.5;CLINICAL STUDIES;328
10.2.3.6;ACKNOWLEDGEMENTS;331
10.2.3.7;REFERENCES;331
10.2.4;CHAPTER 63. HUMAN BREAST CARCINOMA LOCALIZATION WITH A RADIOLABELLED MONOCLONAL
ANTIBODY;332
10.2.4.1;ABSTRACT;332
10.2.4.2;KEYWORDS;332
10.2.4.3;INTRODUCTION;332
10.2.4.4;MATERIALS AND METHODS;332
10.2.4.5;RESULTS;334
10.2.4.6;CONCLUSIONS;336
10.2.4.7;ACKNOWLEDGEMENTS;337
10.2.4.8;REFERENCES;337
10.2.5;CHAPTER 64. RADIOIMMUNODETECTION OF CANCER USING RADIOLABELED ANTIBODIES TO
a-FETOPROTEIN;338
10.2.5.1;ABSTRACT;338
10.2.5.2;KEYWORDS;338
10.2.5.3;INTRODUCTION;338
10.2.5.4;MATERIAL AND METHODS;338
10.2.5.5;RESULTS AND DISCUSSION;339
10.2.5.6;CONCLUSIONS;341
10.2.5.7;REFERENCES;341
10.2.6;CHAPTER 65. RADIOIMMUNOLOCALIZATION OF NON SEMINOMATOUS TESTICULAR TUMOURS SECRETING
ALPHA-FETOPROTEIN;342
10.2.6.1;ABSTRACT;342
10.2.6.2;KEYWORDS;342
10.2.6.3;INTRODUCTION;342
10.2.6.4;PATIENTS AND METHODS;342
10.2.6.5;RESULTS;343
10.2.6.6;DISCUSSION;344
10.2.6.7;REFERENCES;345
10.2.7;CHAPTER
66. MODEL FOR THE RADIOIMMUNODETECTIONOF TUMOURS;346
10.2.7.1;ABSTRACT;346
10.2.7.2;KEYWORDS;346
10.2.7.3;INTRODUCTION;346
10.2.7.4;METHODS;346
10.2.7.5;RESULTS;348
10.2.7.6;ACKNOWLEDGEMENTS;349
10.2.7.7;DISCUSSION;349
10.2.7.8;REFERENCES;349
10.2.8;CHAPTER
67. MICROMETASTASES IN BREAST CANCER;350
10.2.8.1;INTRODUCTION;350
10.2.8.2;Conclusions;356
10.2.8.3;Acknowledgements;356
10.2.8.4;References;356
10.3;..3. Immunohistochemistry;358
10.3.1;CHAPTER 68. IMMUNOHISTOLOGICAL DETERMINATION OF CEA ON BREAST TUMORS: COMPARISON OF MONOCLONAL AND
POLYCLONAL ANTIBODIES;358
10.3.1.1;ABSTRACT;358
10.3.1.2;KEYWORDS;358
10.3.1.3;INTRODUCTION;358
10.3.1.4;MATERIAL AND METHODS;359
10.3.1.5;RESULTS;359
10.3.1.6;DISCUSSION;360
10.3.1.7;REFERENCES;361
10.3.2;CHAPTER 69. IMMUNOHISTOLOGICAL LOCALIZATION OF CARCINOEMBRYONIC ANTIGEN AND NONSPECIFIC CROSSREACTING ANTIGEN
IN BENIGN BREAST LESIONS;362
10.3.2.1;ABSTRACT;362
10.3.2.2;KEYWORDS;362
10.3.2.3;INTRODUCTION;362
10.3.2.4;MATERIALS AND METH;363
10.3.2.5;RESULTS;363
10.3.2.6;DISCUSSION;363
10.3.2.7;ACKNOWLEDGEMENTS;364
10.3.2.8;REFERENCES;364
10.3.3;CHAPTER 70. IMMUNOHISTOCHEMICAL DEMONSTRATION OF CARCINOEMBRYONIC ANTIGEN IN LUNG CANCER, ITS LOCALIZATION IN RELATION TO TUMOR TYPE AND
DIFFERENTIATION;366
10.3.3.1;ABSTRACT;366
10.3.3.2;KEYWORDS;366
10.3.3.3;INTRODUCTION;366
10.3.3.4;MATERIALS AND METHODS;366
10.3.3.5;RESULTS;367
10.3.3.6;DISCUSSION;367
10.3.3.7;REFERENCES;368
10.3.4;CHAPTER 71. IMMUNOHISTOCHEMICAL LOCALIZATION OF SSEA-1 IN NONSEMINOMATOUS TESTICULAR CANCER AND RETROPERITONEAL MATURE TERATOMA
AFTER PVB CHEMOTHERAPY;370
10.3.4.1;ABSTRACT;370
10.3.4.2;KEYWORDS;370
10.3.4.3;INTRODUCTION;370
10.3.4.4;PATIENTS AND METHODS;370
10.3.4.5;RESULTS;371
10.3.4.6;CONCLUSION;372
10.3.4.7;REFERENCES;372
10.3.5;CHAPTER 72. IMMUNOHISTOCHEMISTRY OF TPA:
NOTES ON THE METHODOLOGY;374
10.3.5.1;ABSTRACT;374
10.3.5.2;INTRODUCTION;374
10.3.5.3;METHODS;375
10.3.5.4;DISCUSSION;378
10.3.5.5;ACKNOWLEDGMENT;378
10.3.5.6;REFERENCES;378
10.3.6;CHAPTER 73. GLUCOSE OXIDASE IMMUNOSTAINING
FOR TUMOR MARKER ANTIGENS;380
10.3.6.1;ABSTRACT;380
10.3.6.2;KEYWORDS;380
10.3.6.3;INTRODUCTION;380
10.3.6.4;RESULTS;380
10.3.6.5;ACKNOWLEDGEMENT;383
10.3.6.6;REFERENCES;383
10.3.7;CHAPTER 74. GUANIDINOBENZOATASE AS A MARKER
FOR TUMOUR CELLS;384
10.3.7.1;ABSTRACT;384
10.3.7.2;KEYWORDS;384
10.3.7.3;INTRODUCTION;384
10.3.7.4;REFERENCES;387
10.3.8;CHAPTER 75. ADENOSINE DEAMINASE COMPLEXING PROTEIN: A TRANSFORMATION SENSITIVE MARKER AND POSSIBLE TOOL IN
IMMUNODIAGNOSIS OF SOLID TUMORS;388
10.3.8.1;ABSTRACT;388
10.3.8.2;KEYWORDS;388
10.3.8.3;INTRODUCTION;388
10.3.8.4;METHODS;388
10.3.8.5;RESULTS;389
10.3.8.6;DISCUSSION;391
10.3.8.7;REFERENCES;391
10.3.9;CHAPTER 76. LECTIN- AND IMMUNOHISTOCHEMICAL
ANALYSIS OF RENAL ADENOCARCINOMAS;392
10.3.9.1;ABSTRACT;392
10.3.9.2;KEYWORDS;392
10.3.9.3;INTRODUCTION;392
10.3.9.4;MATERIAL AND METHODS;393
10.3.9.5;RESULTS AND DISCUSSION;393
10.3.9.6;REFERENCES;395
10.3.10;CHAPTER 77. LOCALIZATIONPATTERNSOF CEA AND BETA-HCG IN UNIFORMLY CLASSIFIED
LUNG TUMORS;396
10.3.10.1;ABSTRACT;396
10.3.10.2;KEYWORDS;396
10.3.10.3;INTRODUCTION;396
10.3.10.4;MATERIAL AND METHODS;397
10.3.10.5;PROCEEDING;397
10.3.10.6;RESULTS;397
10.3.10.7;DISCUSSION;399
10.3.10.8;ACKNOWLEDGEMENTS;399
10.3.10.9;REFERENCES;399
10.4;..4. Screening;400
10.4.1;CHAPTER 78. USEFULNESS OF DIFFERENT CANCER
MARKERS IN DAILY ONCOLOGICAL PRACTICE;400
10.4.1.1;INTRODUCTION;400
10.4.1.2;PATIENTS AND METHODS;400
10.4.1.3;RESULTS;401
10.4.1.4;DISCUSSION AND CONCLUSION;402
10.4.2;CHAPTER 79. CAPACITY OF MONOCLONAL „ AND POLYCLONAL ANTLCEA „ ANTIBODIES FOR DISCRIMINATION BETWEEN NORMAL INDIVIDUALS, PATIENTS WITH BENIGN
DISEASE AND PATIENTS WITH CANCER;404
10.4.2.1;ABSTRACT;404
10.4.2.2;INTRODUCTION;404
10.4.2.3;MATERIAL AND METHODS;404
10.4.2.4;DISCUSSION;406
10.4.2.5;ACKNOWLEDGEMENT;407
10.4.2.6;REFERENCES;407
10.4.3;CHAPTER 80. SERUM AMYLOID A PROTEIN AND C-REACTIVE PROTEIN „ A COMPARISON OF SERUM LEVELS IN CANCER AND NON-MALIGNANT
DISEASE;408
10.4.3.1;ABSTRACT;408
10.4.3.2;KEYWORDS;408
10.4.3.3;INTRODUCTION;408
10.4.3.4;MATERIALS AND METHODS;408
10.4.3.5;RESULTS;409
10.4.3.6;CONCLUSION;411
10.4.3.7;REFERENCES;411
10.5;..5. Monitoring;412
10.5.1;B.5.1. Marker oriented;412
10.5.1.1;B.5.1.1. Prealbumin;412
10.5.1.1.1;CHAPTER 81. PREALBUMIN AS A MARKER FOR
CARCINOID TUMOURS;412
10.5.1.1.1.1;ABSTRACT;412
10.5.1.1.1.2;KEYWORDS;412
10.5.1.1.1.3;INTRODUCTION;412
10.5.1.1.1.4;MATERIALS AND METTHODS;413
10.5.1.1.1.5;RESULTS;413
10.5.1.1.1.6;DISCUSSION;414
10.5.1.1.1.7;REFERENCES;415
10.5.1.1.1.8;ACKNOWLEDGEMENTS;415
10.5.1.1.2;CHAPTER 82. ISOLATION OF HUMAN EMBRYONIC
PREALBUMIN FROM AMNIOTIC FLUID;416
10.5.1.1.2.1;ABSTRACT;416
10.5.1.1.2.2;KEYWORDS;416
10.5.1.1.2.3;INTRODUCTION;416
10.5.1.1.2.4;MATERIALS AND METHODS;416
10.5.1.1.2.5;IMMUNOLOGICAL SCREENING;417
10.5.1.1.2.6;DYE AFFINITY CHROMATOGRAPHY;417
10.5.1.1.2.7;SEPHAROSE ION EXCHANGE CHROMATOGRAPHY;417
10.5.1.1.2.8;RESULTS;417
10.5.1.1.2.9;DISCUSSION;418
10.5.1.1.2.10;ACKNOWLEDGEMENTS;418
10.5.1.1.2.11;REFERENCES;419
10.5.1.2;B.5.1.2 AIfa-Foetoprotein;420
10.5.1.2.1;CHAPTER 83. MOLECULAR SPECIES OF HUMAN a- FETOPROTEIN AND .- OLUTAMYLTRANSFERASE MORE SPECIFIC TO HEPATOCELLULAR CARCINOMA; DEMONSTRATION BY DIFFERENTIAL AFFINITIES TO
LECTINS;420
10.5.1.2.1.1;ABSTRACT;420
10.5.1.2.1.2;KEYWORDS;420
10.5.1.2.1.3;INTRODUCTION;420
10.5.1.2.1.4;MATERIALS AND METHODS;420
10.5.1.2.1.5;RESULTS;421
10.5.1.2.1.6;DISCUSSION;422
10.5.1.2.1.7;ACKNOWLEDGEMENT;423
10.5.1.2.1.8;REFERENCES;423
10.5.1.2.2;CHAPTER 84. IMMUNOHISTOCHEMICAL STUDY ON ALPHA-FETOPROTEIN IN RATS DURING
FETAL AND POST-NATAL LIFE;424
10.5.1.2.2.1;ABSTRACT;424
10.5.1.2.2.2;KEYWORDS;424
10.5.1.2.2.3;INTRODUCTION;424
10.5.1.2.2.4;MATERIALS AND METHODS;424
10.5.1.2.2.5;RESULTS;425
10.5.1.2.2.6;DISCUSSION;427
10.5.1.2.2.7;REFERENCES;427
10.5.1.2.3;CHAPTER 85. MONITORING VERY LOW LEVELS OF AFP IN THE EARLY DETECTION OF
TUMOR RECURRENCY;428
10.5.1.2.3.1;ABSTRACT;428
10.5.1.2.3.2;KEYWORDS;428
10.5.1.2.3.3;INTRODUCTION;428
10.5.1.2.3.4;METHODS;428
10.5.1.2.3.5;RESULTS;429
10.5.1.2.3.6;ACKNOWLEDGEMENTS;431
10.5.1.2.3.7;REFERENCES;431
10.5.1.3;B.5.1.3. Oncomodulin;432
10.5.1.3.1;CHAPTER 86. THE POTENTIAL OF THE CALCIUM-BINDING PROTEIN, ONCOMODULIN,
AS A TUMOUR MARKER;432
10.5.1.3.1.1;ABSTRACT;432
10.5.1.3.1.2;KEY WORDS;432
10.5.1.3.1.3;INTRODUCTION;432
10.5.1.3.1.4;RESULTS AND DISCUSSION;432
10.5.1.3.1.5;ACKNOWLEDGEMENTS;436
10.5.1.3.1.6;REFERENCES;436
10.5.1.3.2;CHAPTER 87. THE BINDING OF DIVALENT CATIONS
TO ONCOMODULIN;438
10.5.1.3.2.1;ABSTRACT;438
10.5.1.3.2.2;KEY WORDS;438
10.5.1.3.2.3;INTRODUCTION;438
10.5.1.3.2.4;RESULTS AND DISCUSSION;438
10.5.1.3.2.5;ACKNOWLEDGEMENTS;441
10.5.1.3.2.6;REFERENCES;441
10.5.1.4;B.5.1.4 S-100;442
10.5.1.4.1;CHAPTER 88. THE S-100 ANTIGEN IN NON-NEURAL
TUMOURS;442
10.5.1.4.1.1;ABSTRACT;442
10.5.1.4.1.2;KEYWORDS;442
10.5.1.4.1.3;INTRODUCTION;442
10.5.1.4.1.4;EXPERIMENTALP ROCEDURES;442
10.5.1.4.1.5;RESULTS
AND DISCUSSION;443
10.5.1.4.1.6;REFERENCES;445
10.5.1.4.2;CHAPTER 89. S-100PROTEINDECREASES THE FLUIDITY OF THE LIPID BILAYER OF PURIFIED SYNAPTIC
PLASMA MEMBRANES;446
10.5.1.4.2.1;AB8TRACT;446
10.5.1.4.2.2;KEYWORDS;446
10.5.1.4.2.3;INTRODUCTION;446
10.5.1.4.2.4;MATERIALS
AND METHODS;447
10.5.1.4.2.5;RESULTS;447
10.5.1.4.2.6;DISCUSSION;448
10.5.1.4.2.7;REFERENCES;449
10.5.1.5;B.5.1.5. Blood Group T;450
10.5.1.5.1;CHAPTER 90. BLOOD GROUP . AND TN ANTIGENS ARE

EPITHELIAL CELL-ADHESIVE, UNIVERSAL,

CLONAL, AUTOIMMUNOGENIC

CARCINOMA
MARKERS;450
10.5.1.5.1.1;ABSTRACT;450
10.5.1.5.1.2;TN AND . ANTIGENS ARE CLONAL CA MARKERS;451
10.5.1.5.1.3;. AND TN ANTIGENS IN CANCER CELL ADHESION;451
10.5.1.5.1.4;IMMUNE RESPONSES AGAINST CA-ASSOCIATED . ANTIGEN;451
10.5.1.5.1.5;REFERENCES;453
10.5.1.5.2;CHAPTER
91. CARCINOMA DETECTION BY QUANTITATION AND INTERRELATION OF SERUM ANTI-T IgM AND TOTAL IgM;454
10.5.1.5.2.1;ABSTRACT;454
10.5.1.5.2.2;REFERENCES;456
10.5.1.6;B.5.1.6. TPA;458
10.5.1.6.1;CHAPTER
92. OVERVIEW OF TPA: SPECIFICITY, IMMUNOCHEMISTRY, AND BIOLOGICAL BASIS;458
10.5.1.6.1.1;ABSTRACT;458
10.5.1.6.1.2;INTRODUCTION;458
10.5.1.6.1.3;EXPERIMENTAL;458
10.5.1.6.1.4;IMMUNOCHEMISTRY;459
10.5.1.6.1.5;SPECIFICITY;460
10.5.1.6.1.6;BIOLOGICAL BASIS;460
10.5.1.6.1.7;DISCUSSION;461
10.5.1.6.1.8;ACKNOWLEDGEMENT;462
10.5.1.6.1.9;REFERENCES;463
10.5.1.6.2;CHAPTER 93. HETEROLOGOUS AND HOMOLOGOUS ANTI-TPA
ANTIBODIES;464
10.5.1.6.2.1;ABSTRACT;464
10.5.1.6.2.2;INTRODUCTION;464
10.5.1.6.2.3;EXPERIMENTAL;464
10.5.1.6.2.4;DISCUSSION;468
10.5.1.6.2.5;ACKNOWLEDGEMENT;468
10.5.1.6.2.6;REFERENCES;468
10.5.1.6.3;CHAPTER 94. DISTRIBUTION OF TISSUE POLYPEPTIDE ANTIGEN IN NORMAL AND NEOPLASTIC HUMAN
TISSUES;470
10.5.1.6.3.1;ABSTRACT;470
10.5.1.6.3.2;KEYWORDS;470
10.5.1.6.3.3;INTRODUCTION;470
10.5.1.6.3.4;MATERIAL AND METHODS;470
10.5.1.6.3.5;RESULTS;471
10.5.1.6.3.6;DISCUSSION;473
10.5.1.6.3.7;ACKNOWLEDGEMENT;473
10.5.1.6.3.8;REFERENCES;473
10.5.1.6.4;CHAPTER 95. SERUM LEVELS OF TPA IN PATIENTS WITH GYNAECOLOGICAL
CANCER;474
10.5.1.6.4.1;ABSTRACT;474
10.5.1.6.4.2;KEYWORDS;474
10.5.1.6.4.3;INTRODUCTION;474
10.5.1.6.4.4;MATERIALS AND METHODS;474
10.5.1.6.4.5;RESULTS;475
10.5.1.6.4.6;DISCUSSION;477
10.5.1.6.4.7;ACKNOWLEDGEMENT;477
10.5.1.6.4.8;REFERENCES;477
10.5.1.6.5;CHAPTER
96. MONITORING OF BREAST CANCER WITH THE AID OF TISSUE POLYPEPTIDE ANTIGEN;478
10.5.1.6.5.1;ABSTRACT;478
10.5.1.6.5.2;INTRODUCTION;478
10.5.1.6.5.3;METHODS;478
10.5.1.6.5.4;MONITORING OF EARLY RECURRENCE;478
10.5.1.6.5.5;MONITORING OF RESPONSE TO SYSTEMIC THERAPY;479
10.5.1.6.5.6;CONCLUSIONS;480
10.5.1.6.5.7;REFERENCES;480
10.5.1.6.6;CHAPTER
97. TISSUE POLYPEPTIDE ANTIGEN IN PATIENTS WITH BREAST CANCER AND GYNECOLOGICAL CANCER;482
10.5.1.6.6.1;ABSTRACT;482
10.5.1.6.6.2;KEYWORDS;482
10.5.1.6.6.3;INTRODUCTION;482
10.5.1.6.6.4;MATERIALS AND METHODS;482
10.5.1.6.6.5;RESULTS;483
10.5.1.6.6.6;DISCUSSION;484
10.5.1.6.6.7;REFERENCES;485
10.5.1.6.7;CHAPTER
98. TISSUE TUMOR POLYPEPTIDE ANTIGEN AND GASTROINTESTINAL CANCER;486
10.5.1.6.7.1;RESULTS;487
10.5.1.6.7.2;REFERENCES;489
10.5.1.6.8;CHAPTER 98. MOLECULAR WEIGHT HETEROGENEITY OF TISSUE POLYPEPTIDE
ANTIGEN IN CANCER SERA;490
10.5.1.6.8.1;ABSTRACT;490
10.5.1.6.8.2;KEYWORDS;490
10.5.1.6.8.3;INTRODUCTION;491
10.5.1.6.8.4;MATERIAL AND METHODS;491
10.5.1.6.8.5;RESULTS AND DISCUSSION;491
10.5.1.6.8.6;References;495
10.5.1.6.9;CHAPTER 99. MONOCLONAL ANTIBODIES AGAINST TISSUE POLYPEPTIDE
ANTIGEN;496
10.5.1.6.9.1;ABSTRACT;496
10.5.1.6.9.2;KEYWORDS;496
10.5.1.6.9.3;INTRODUCTION;496
10.5.1.6.9.4;MATERIAL AND METHODS;497
10.5.1.6.9.5;RESULTS AND DISCUSSION;497
10.5.1.6.10;CHAPTER 100. TUMOR GROWTH, CIRCULATING

HUMAN CEA, ß-2-MICROGLOBULIN

AND
TISSUE-POLYPEPTIDE-ANTIGEN

IN XENOGRAFTED NUDE MICE;500
10.5.1.6.10.1;ABSTRACT;500
10.5.1.6.10.2;KEYWORDS;500
10.5.1.6.10.3;INTRODUCTION;500
10.5.1.6.10.4;RESULTS;501
10.5.1.6.10.5;DISCUSSION;502
10.5.1.6.10.6;ACKNOWLEDGEMENTS;503
10.5.1.6.10.7;REFERENCES;503
10.5.1.6.11;CHAPTER
101. SIGNIFICANCE OF hTG, CEA AND TPA AS TUMOR MARKERS IN THYROID CANCER;504
10.5.1.6.11.1;ABSTRACT;504
10.5.1.6.11.2;KEYWORDS;504
10.5.1.6.11.3;INTRODUCTION;504
10.5.1.6.11.4;MATERIAL AND METHODS;504
10.5.1.6.11.5;RESULTS;505
10.5.1.6.11.6;DISCUSSION;505
10.5.1.6.11.7;REFERENCES;507
10.5.1.6.12;CHAPTER
102. SENSITIVITY AND SPECIFICITY OF TPA, CEA, AND THE INDEX OF BOTH MARKERS IN VARIOUS MALIGNANCIES;508
10.5.1.6.12.1;ABSTRACT;508
10.5.1.6.12.2;KEY WORDS;508
10.5.1.6.12.3;INTRODUCTION;508
10.5.1.6.12.4;MATERIAL AND METHODS;508
10.5.1.6.12.5;RESULTS;509
10.5.1.6.12.6;DISCUSSION;511
10.5.1.6.12.7;REFERENCES;511
10.5.1.6.13;CHAPTER
103. EVALUATION OF AFP, ß-HCG, TAG, CEA, AND SP1 IN PATIENTS WITH MALIGNOMA OF THE TESTIS;512
10.5.1.6.13.1;ABSTRACT;512
10.5.1.6.13.2;KEYWORDS;512
10.5.1.6.13.3;INTRODUCTION;512
10.5.1.6.13.4;MATERIALS AND METHODS;512
10.5.1.6.13.5;RESULTS;513
10.5.1.6.13.6;DISCUSSION;514
10.5.1.6.13.7;ACKNOWLEDGEMENT;515
10.5.1.6.13.8;REFERENCES;515
10.5.1.6.14;CHAPTER
104. CLINICAL USE OF TPA IN CANCER OF THE URINARY BLADDER USING CEA FOR COMPARISON;516
10.5.1.6.14.1;ABSTRACT;516
10.5.1.6.14.2;KEY OOIDS;516
10.5.1.6.14.3;INTRODUCTION;516
10.5.1.6.14.4;MATERIAL AND
METHODS;516
10.5.1.6.14.5;REFERENCES;516
10.5.1.6.14.6;RESULTS;517
10.5.1.6.14.7;DISCUSSION;518
10.5.1.6.15;CHAPTER 105. CLINICAL SIGNIFICANCE OF COMBINED TPA AND CEA DETERMINATIONS DURING CHEMOTHERAPY AND/OR RADIOTHERAPY IN PATIENTS WITH BREAST
CANCER OR LUNG CANCER;520
10.5.1.6.15.1;ABSTPACT;520
10.5.1.6.15.2;KEY WORDS;520
10.5.1.6.15.3;INTRODUCTION;520
10.5.1.6.15.4;MATERIAL AND
METHODS;520
10.5.1.6.15.5;RESULTS;520
10.5.1.6.15.6;DISCUSSION;521
10.5.1.6.15.7;REFERENCES;522
10.5.1.6.16;CHAPTER
106. SENSITIVITY AND SPECIFICITY OF TENNESSEE ANTIGEN IN COMPARISON TO CEA, TPA, AND THEIR OPTIMAL COMBINATIONS;524
10.5.1.6.16.1;ABSTRACT;524
10.5.1.6.16.2;KEYWORDS;524
10.5.1.6.16.3;INTRODUCTION;524
10.5.1.6.16.4;MATERIAL AND METHODS;524
10.5.1.6.16.5;RESULTS;525
10.5.1.6.16.6;DISCUSSION;525
10.5.1.6.16.7;ACKNOWLEDGEMENT;527
10.5.1.6.16.8;REFERENCES;527
10.5.1.6.17;CHAPTER
107. COMPARISON OF SINGLE AND COMBINED CEA AND TPA DETERMINATION FOR TUMOR DETECTION IN VARIOUS CANCER PATIENTS;528
10.5.1.6.17.1;ABSTRACT;528
10.5.1.6.17.2;KEYWORDS;528
10.5.1.6.17.3;INTRODUCTION;528
10.5.1.6.17.4;MATERIAL AND METHODS;528
10.5.1.6.17.5;RESULTS;529
10.5.1.6.17.6;DISCUSSION;529
10.5.1.6.17.7;REFERENCES;530
10.5.1.6.18;CHAPTER
108. INITIAL EXPERIENCE WITH TPA, CA-125 AND CRP AS TUMOR MARKERS IN OVARIAN MALIGNANCY;532
10.5.1.6.18.1;INTRODUCTION;532
10.5.1.6.18.2;MATERIAL AND METHODS;532
10.5.1.6.18.3;RESULTS;533
10.5.1.6.18.4;DISCUSSION;535
10.5.1.6.18.5;ACKOWLEDGEMENTS;535
10.5.1.6.18.6;REFERENCES;535
10.5.1.6.19;CHAPTER 109. SERIAL MONITORING OF CEA, TPA AND TENNESSEE ANTIGEN
DURING TREATMENT OF TUMOR PATIENTS BY ADJUVANT IMMUNOTHERAPY WITH OK 432;536
10.5.1.6.19.1;ABSTRACT;536
10.5.1.6.19.2;KEYWORDS;536
10.5.1.6.19.3;INTRODUCTION;536
10.5.1.6.19.4;MTERIAL AND METHODS;536
10.5.1.6.19.5;RESULTS;537
10.5.1.6.19.6;DISCUSSION;538
10.5.1.6.19.7;REFERENCES;539
10.5.1.6.20;CHAPTER
110. CEA AND TPA IN PLASMA, CEREBROSPINAL FLUID AND TUMOR HOMOGENATE OF PATIENTS WITH PRIMARY INTRACRANIAL TUMORS;540
10.5.1.6.20.1;ABSTRACT;540
10.5.1.6.20.2;KEY WORDS;540
10.5.1.6.20.3;INTRODUCTION;540
10.5.1.6.20.4;MATERIAL AND METHODS;541
10.5.1.6.20.5;RESULTS;541
10.5.1.6.20.6;DISCUSSION;541
10.5.1.6.20.7;REFERENCES;542
10.5.1.7;B.5.1.7. Various Markers;544
10.5.1.7.1;CHAPTER 111. ANTISERA AGAINST CIRCULATING HUMAN TUMOR ASSOCIATED
ANTIGENS;544
10.5.1.7.1.1;ABSTRACT;544
10.5.1.7.1.2;KEYWORDS;544
10.5.1.7.1.3;INTRODUCTION;544
10.5.1.7.1.4;RESULTS;545
10.5.1.7.1.5;DISCUSSION;547
10.5.1.7.1.6;ACKNOWLEDGEMENTS;549
10.5.1.7.1.7;REFERENCES;549
10.5.1.7.2;CHAPTER 112. USEFULNESS OF THE ACIDIC ISOFERRITIN ASSAY
FOR DIAGNOSIS OF MALIGNANCIES;550
10.5.1.7.2.1;ABSTRACT;550
10.5.1.7.2.2;KEYWORDS;550
10.5.1.7.2.3;INTRODUCTION;550
10.5.1.7.2.4;MATERIALS AND METHODS;550
10.5.1.7.2.5;RESULTS;551
10.5.1.7.2.6;DISCUSSION;553
10.5.1.7.2.7;REFERENCES;553
10.5.1.7.3;CHAPTER
113. PATTERNS OF EXPRESSION OF SOME NEW ANTIGENS OF HUMAN BRONCHIAL CARCINOMAS;554
10.5.1.7.3.1;ABSTRACT;554
10.5.1.7.3.2;KEYWORDS;554
10.5.1.7.3.3;INTRODUCTION;554
10.5.1.7.3.4;MATERIALS AND METHODS;555
10.5.1.7.3.5;RESULTS;556
10.5.1.7.3.6;DISCUSSION;557
10.5.1.7.3.7;REFERENCES;557
10.5.2;B.5.2. Organ oriented;558
10.5.2.1;B.5.2.1. Mammary Tumor;558
10.5.2.1.1;CHAPTER 114. CLINICAL IMPORTANCE OF CEA AND FERRITIN IN LUNG AND BREAST
CANCER;558
10.5.2.1.1.1;INTRODUCTION;558
10.5.2.1.1.2;PATIENTS AND METHODS;558
10.5.2.1.1.3;RESULTS;559
10.5.2.1.1.4;CONCLUSION;561
10.5.2.1.2;CHAPTER
115. CEA IN BREAST CARCINOMA. MORPHOLOGICAL RESULTS IN CORRELATION WITH PLASMA VALUES;562
10.5.2.1.2.1;ABSTRACT;562
10.5.2.1.2.2;KEYWORDS;562
10.5.2.1.2.3;INTRODUCTION;562
10.5.2.1.2.4;MATERIAL AND METHODS;562
10.5.2.1.2.5;RESULTS;563
10.5.2.1.2.6;CONCLUSIONS;564
10.5.2.1.2.7;REFERENCES;564
10.5.2.1.3;CHAPTER 116. USE OF SERUM PHOSPHOHEXOSE ISOMERASE AND CEA DETERMINATIONS IN CLINICAL MANAGEMENT OF BREAST CANCER;566
10.5.2.1.3.1;INTRODUCTION;566
10.5.2.1.3.2;KEYWORDS;566
10.5.2.1.3.3;MATERIAL AND METHODS;566
10.5.2.1.3.4;RESULTS;567
10.5.2.1.3.5;DISCUSSION;568
10.5.2.1.3.6;ACKNOWLEDGEMENTS;569
10.5.2.1.3.7;REFERENCES;569
10.5.2.1.4;CHAPTER
117. CORRELATION BETWEEN CEA SERUM LEVELS AND ESTROGEN RECEPTORS IN BREAST CANCER;570
10.5.2.1.4.1;INTRODUCTION;570
10.5.2.1.4.2;KEYWORDS;570
10.5.2.1.4.3;MATERIAL AND METHODS;570
10.5.2.1.4.4;RESULTS;571
10.5.2.1.4.5;DISCUSSION;572
10.5.2.1.4.6;CONCLUSIONS;573
10.5.2.1.4.7;ACKNOWLEDGEMENTS;573
10.5.2.1.4.8;REFERENCES;573
10.5.2.1.5;CHAPTER
118. THE 126 KD PHOSPHOPROTEIN OF HUMAN BREAST CARCINOMA CELL SURFACE;574
10.5.2.1.5.1;INTRODUCTION;574
10.5.2.1.5.2;SUMMARY;577
10.5.2.1.5.3;REFERENCES;578
10.5.2.1.6;CHAPTER
119. PRETREATMENT SERUM CEA LEVEL IS AN INDEPENDENT PROGNOSTIC FACTOR IN BREAST AND LUNG CANCER PATIENTS;580
10.5.2.1.6.1;ABSTRACT.;580
10.5.2.1.6.2;KEYWORDS.;580
10.5.2.1.6.3;INTRODUCTION.;580
10.5.2.1.6.4;MATERIAL
AND METHODS;581
10.5.2.1.6.5;RESULTS.;581
10.5.2.1.6.6;CONCLUSIONS.;583
10.5.2.1.7;CHAPTER
120. PLACENTAL PROTEIN 10 (PPIO) IN BREAST CANCER AND GENITAL CARCINOMA;584
10.5.2.1.7.1;ABSTRACT;584
10.5.2.1.7.2;KEYWORDS;584
10.5.2.1.7.3;INTRODUCTION;584
10.5.2.1.7.4;PATIENTS AND METHODS;584
10.5.2.1.7.5;RESULTS AND DISCUSSION;585
10.5.2.1.7.6;ACKNOWLEDGEMENT;587
10.5.2.1.7.7;REFERENCES;587
10.5.2.1.8;CHAPTER 121. COMPARISON OF CEA AND SP-1 TISSUE POSITIVITY IN HUMAN MAMMARY
CARCINOMAS;588
10.5.2.1.8.1;ABSTRACT;588
10.5.2.1.8.2;KEYWORDS;588
10.5.2.1.8.3;INTRODUCTION;588
10.5.2.1.8.4;MATERIAL AND METHODS;589
10.5.2.1.8.5;RESULTS;589
10.5.2.1.8.6;DISCUSSION;590
10.5.2.1.8.7;ACKNOWLEDGEMENTS;591
10.5.2.1.8.8;REFERENCES;591
10.5.2.1.9;CHAPTER 122. IMMUNOPEROXIDASE LOCALISATION OF Ca ANTIGEN IN MAMMARY
TUMOURS;592
10.5.2.1.9.1;INTRODUCTION;592
10.5.2.1.9.2;MATERIALS AND METHODS;592
10.5.2.1.9.3;RESULTS AND DISCUSSION;593
10.5.2.1.9.4;ACKNOWLEDGEMENTS;595
10.5.2.1.9.5;REFERENCES;595
10.5.2.1.10;CHAPTER 123. BIOCHEMICAL AND IMMUNOHISTO-CHEMICAL CHARACTERIZATION OF A PEANUT AGGLUTININ
BINDING GLYCOPROTEIN IN NORMAL AND MALIGNANT BREAST TISSUES;596
10.5.2.1.10.1;ABSTRACT;596
10.5.2.1.10.2;KEYWORDS;596
10.5.2.1.10.3;INTRODUCTION;596
10.5.2.1.10.4;MATERIAL AND METHODS;597
10.5.2.1.10.5;RESULTS AND
DlSCUSSION;597
10.5.2.1.10.6;REFERENCES;599
10.5.2.1.11;CHAPTER
124. UTILIZATION OF THE GCDFP-15 PROTEIN AS A MARKER OF BREAST CARCINOMAS WITH APOCRINE FEATURES: CLINICAL AND PATHOLOGICAL FINDINGS;600
10.5.2.1.11.1;ACKNOWLEDGEMENT;603
10.5.2.1.11.2;REFERENCES;603
10.5.2.1.12;CHAPTER
125. USEFULNESS OF THE DETERMINATION OF PHOSPHOHEXOSE ISOMERASE AND CARCINOEMBRYONIC ANTIGEN IN THE EARLY DETECTION OF METASTASES OF BREAST CANCER;604
10.5.2.1.12.1;INTRODUCTION;604
10.5.2.1.12.2;KEYWORDS;604
10.5.2.1.12.3;MATERIALS AND METHODS;604
10.5.2.1.12.4;RESULTS;604
10.5.2.1.12.5;DISCUSSION;606
10.5.2.1.12.6;ACKNOWLEDGEMENTS;606
10.5.2.1.12.7;REFERENCES;606
10.5.2.1.13;CHAPTER
126. SERUM TUMOR MARKERS IN PATIENTS WITH PRIMARY BREAST CANCER AND DURING THE FOLLOW-UP;608
10.5.2.1.13.1;ABSTRACT;608
10.5.2.1.13.2;KEYWORDS;608
10.5.2.1.13.3;INTRODUCTION;608
10.5.2.1.13.4;PATIENTS AND METHODS;608
10.5.2.1.13.5;RESULTS;609
10.5.2.1.13.6;CONCLUSIONS;611
10.5.2.1.13.7;REFERENCES;611
10.5.2.2;A.5.2.2. Gastrointestinal Tumors;612
10.5.2.2.1;CHAPTER
127. COMMON AND SPECIFIC ANTIGENS ON TWO TUMOR CELL LINES;612
10.5.2.2.1.1;ABSTRACT;612
10.5.2.2.1.2;KEYWORDS;612
10.5.2.2.1.3;INTRODUCTION;612
10.5.2.2.1.4;MATERIAL AND METHODS;612
10.5.2.2.1.5;DISCUSSION;615
10.5.2.2.1.6;REFERENCES;615
10.5.2.2.2;CHAPTER
128. IMMUNOLOGICAL ASSAY OF SERUM RIBONUCLEASEASA MARKERFOR PANCREATICCANCER;616
10.5.2.2.2.1;ABSTRACT;616
10.5.2.2.2.2;KEYWORDS;616
10.5.2.2.2.3;INTRODUCTION;616
10.5.2.2.2.4;REFERENCES;619
10.5.2.2.3;CHAPTER
129. TUMOR CELL HETEROGENEITY IN PRIMARY AND METASTATIC COLORECTAL CARCINOMA;620
10.5.2.2.3.1;ABSTRACT;620
10.5.2.2.3.2;KEYWORDS;621
10.5.2.2.3.3;INTRODUCTION;621
10.5.2.2.3.4;MATERIALS AND METHODS;621
10.5.2.2.3.5;RESULTS;623
10.5.2.2.3.6;DISCUSSION;625
10.5.2.2.3.7;ACKNOWLEDGEMENTS;626
10.5.2.2.3.8;REFERENCES;626
10.5.2.2.4;CHAPTER 130. A GENERAL TUMOR MARKER IN RATS WHICH IS RECOGNIZED
BY THE HEPATIC ASIALOGLYCOPROTEIN RECEPTOR;628
10.5.2.2.4.1;ABSTRACT;628
10.5.2.2.4.2;KEYWORDS;628
10.5.2.2.4.3;MATERIAL
AND METHODS;628
10.5.2.2.4.4;RESULTS;629
10.5.2.2.4.5;DISCUSSION;631
10.5.2.2.4.6;REFERENCES;631
10.5.2.2.5;CHAPTER
131. LUNG AND GASTROINTESTINAL TUMOR CELLS SECRETE PEPTIDE HORMONES;632
10.5.2.2.5.1;ABSTRACT;632
10.5.2.2.5.2;KEYUDRDS;632
10.5.2.2.5.3;INTRODUCTION;632
10.5.2.2.5.4;nETHGDS;632
10.5.2.2.5.5;RESULTS;634
10.5.2.2.5.6;DISCUSSION;634
10.5.2.2.5.7;REFERENCES;635
10.5.2.2.6;CHAPTER
132. ALTERED GLYCOPROTEIN SECRETION IN GASTROINTESTINAL MALIGNANCY. ITS VALUE IN ASSESSING HIGH RISK CANCER PATIENTS;636
10.5.2.2.6.1;REFERENCES;639
10.5.2.2.7;CHAPTER
133. DO BILE ACID RECEPTORS EXIST IN HUMAN COLORECTAL CANCER?;640
10.5.2.2.7.1;ABSTRACT;640
10.5.2.2.7.2;KEYWORDS;640
10.5.2.2.7.3;INTRODUCTION;640
10.5.2.2.7.4;METHODS & MATERIALS;641
10.5.2.2.7.5;RESULTS;641
10.5.2.2.7.6;DISCUSSION;643
10.5.2.2.7.7;ACKNOWLEDGEMENTS;643
10.5.2.2.7.8;REFERENCES;643
10.5.2.2.8;CHAPTER
134. ISOLATION OF LECTIN BINDING GLYCOPROTEINS FROM NORMAL AND MALIGNANT GASTRIC MUCOSA;644
10.5.2.2.8.1;ABSTRACT;644
10.5.2.2.8.2;KEYWORDS;644
10.5.2.2.8.3;INTRODUCTION;644
10.5.2.2.8.4;MATERIAL AND METHODS;645
10.5.2.2.8.5;RESULTS AND
DISCUSSION;645
10.5.2.2.8.6;REFERENCES;647
10.5.2.3;B.5.2.3. Reproductive Organs;648
10.5.2.3.1;CHAPTER 135. IMMUNOBIOLOGIC MARKERS IN BENIGN AND MALIGNANT TUMOUR OF THE PROSTATE;648
10.5.2.3.1.1;ABSTRACT;648
10.5.2.3.1.2;KEY WORDS;648
10.5.2.3.1.3;INTRODUCTION;648
10.5.2.3.1.4;MATERIALS AND METHODS;649
10.5.2.3.1.5;RESULTS;649
10.5.2.3.1.6;DISCUSSION;651
10.5.2.3.1.7;REFERENCES;651
10.5.2.3.2;CHAPTER
136. POSSIBILITIES AND LIMITATIONS OF THE IMMUNOLOGICAL DETECTION OF PROSTATIC ACID PHOSPHATASE;652
10.5.2.3.2.1;ABSTRACT;652
10.5.2.3.2.2;KEYWORDS;652
10.5.2.3.2.3;INTRODUCTION;652
10.5.2.3.2.4;METHODS;653
10.5.2.3.2.5;RESULTS;653
10.5.2.3.2.6;DISCUSSION;655
10.5.2.3.2.7;ACKNOWLEGDMENT;656
10.5.2.3.2.8;REFERENCES;657
10.5.2.3.3;CHAPTER
137. IMMUNOCHEMICAL ESTIMATION OF PAP;658
10.5.2.3.3.1;ABSTFLACT;658
10.5.2.3.3.2;KEYWORDS;658
10.5.2.3.3.3;INTRODUCTION;658
10.5.2.3.3.4;MATERIAL AND
METHODS;658
10.5.2.3.3.5;RESULTS;659
10.5.2.3.3.6;DISCUSSION;660
10.5.2.3.3.7;REFERENCES;661
10.5.2.3.4;CHAPTER

138. ALKALINE PHOSPHATASE AND GAMMA-GLUTAMYL TRANSPEPTIDASE AND ISOENZYME PATTERN OF AP IN PATIENTS WITH STAGE HI NONSEMINOMATOUS TESTICULAR TUMORS;662
10.5.2.3.4.1;ABSTRACT;662
10.5.2.3.4.2;KEYWORDS;662
10.5.2.3.4.3;INTRODUCTION;662
10.5.2.3.4.4;PATIENTS AND METHODS;663
10.5.2.3.4.5;RESULTS;663
10.5.2.3.4.6;DISCUSSION;665
10.5.2.3.4.7;REFERENCES;665
10.5.2.3.5;CHAPTER
139. SERUMFERRITIN IN PATIENTS WITH NONSEMINOMATOUS TESTICULAR TUMORS;666
10.5.2.3.5.1;ABSTRACT;666
10.5.2.3.5.2;KEYWORDS;666
10.5.2.3.5.3;INTRODUCTION;666
10.5.2.3.5.4;PATIENTS AND METHODS;667
10.5.2.3.5.5;RESULTS;667
10.5.2.3.5.6;DISCUSSION;667
10.5.2.3.5.7;REFERENCES;669
10.5.2.3.6;CHAPTER
140. VALUE OF TUMOR MARKER DETERMINATIONS IN PATIENTS WITH OVARIAN AND UTERINE CANCER;670
10.5.2.3.6.1;ABSTRACT;670
10.5.2.3.6.2;KEYWORDS;670
10.5.2.3.6.3;INTRODUCTION;670
10.5.2.3.6.4;METHODS AND PATIENTS;670
10.5.2.3.6.5;RESULTS;670
10.5.2.3.6.6;DISCUSSION
AND CONCLUSIONS;673
10.5.2.3.6.7;REFERENCES;673
10.5.2.3.7;CHAPTER
141. A SERUM ANDROGEN'BINDING PROTEIN DISTINCT FROM SEX HORMONE-BINDING GLOBULIN IN PATIENTS WITH HYDA TIDIFORM MOLE;674
10.5.2.3.7.1;ABSTRACT;674
10.5.2.3.7.2;KEY WORDS;674
10.5.2.3.7.3;INTRODUCTION;674
10.5.2.3.7.4;MATERIALS AND METHODS;675
10.5.2.3.7.5;RESULTS;675
10.5.2.3.7.6;DISCUSSION;677
10.5.2.3.7.7;AKNOWLEDGEMENTS;677
10.5.2.3.7.8;REFERENCES;677
10.5.2.3.8;CHAPTER
142. TUMOUR MARKERS IN GYNAECOLOGICAL TUMOURS;678
10.5.2.3.8.1;ABSTRACT;678
10.5.2.3.8.2;KEYWORDS;678
10.5.2.3.8.3;INTRODUCTION;678
10.5.2.3.8.4;MATERIAL AND METHODS;679
10.5.2.3.8.5;RESULTS;679
10.5.2.3.8.6;REFERENCES;682
10.5.2.4;..5.2.4. Hematological Disorders;684
10.5.2.4.1;B.5.2.4.1. Lymphocytes;684
10.5.2.4.1.1;CHAPTER
143. BETA-2-MICROGLOBULIN IN HÄEMATOLOGICAL MALIGNANCY;684
10.5.2.4.1.1.1;REFERENCES;687
10.5.2.4.1.2;CHAPTER 144. MODULATION OF LYMPHOPROLIFERATIVE RESPONSES BY CYTOSOL FRACTION OF RAT
FIBROSARCOMA;688
10.5.2.4.1.2.1;ABSTRACT;688
10.5.2.4.1.2.2;INTRODUCTION;688
10.5.2.4.1.2.3;MATERIALS AND METHODS;688
10.5.2.4.1.2.4;RESULTS;689
10.5.2.4.1.2.5;CONCLUSION;691
10.5.2.4.1.2.6;REFERENCES;691
10.5.2.4.1.3;CHAPTER
145. PHOSPHOHEXOSE ISOMERASE ACTIVITY IN LYMPHOCYTE CULTURES FROM CANCER PATIENTS;692
10.5.2.4.1.3.1;ABSTRACT;692
10.5.2.4.1.3.2;KEYWORDS;692
10.5.2.4.1.3.3;INTRODUCTION;692
10.5.2.4.1.3.4;MATERIALS AND METHODS;693
10.5.2.4.1.3.5;RESULTS;693
10.5.2.4.1.3.6;DISCUSSION;694
10.5.2.4.1.3.7;ACKNOWLEDGEMENTS;695
10.5.2.4.1.3.8;REFERENCES;695
10.5.2.4.1.4;CHAPTER
146. AMP-DEAMINASE AND CYTOSOLIC 5-NUCLEOTIDASE INVOLVEMENT IN LYMPHOCYTE MATURATION;696
10.5.2.4.1.4.1;ABSTRACT;696
10.5.2.4.1.4.2;KEY WORDS;696
10.5.2.4.1.4.3;INTRODUCTION;696
10.5.2.4.1.4.4;MATERIALS AND METHODS;697
10.5.2.4.1.4.5;RESULTS;697
10.5.2.4.1.4.6;ACKNOWLEDGEMENTS;699
10.5.2.4.1.4.7;REFERENCES;699
10.5.2.4.1.5;CHAPTER
147. DETECTION OF DR ANTIGENS ON HUMAN MALIGNANT LYMPHOCYTES;700
10.5.2.4.1.5.1;ABSTRACT;700
10.5.2.4.1.5.2;KEY WORDS;700
10.5.2.4.1.5.3;INTRODUCTION;700
10.5.2.4.1.5.4;MATERIAL AND METHODS;700
10.5.2.4.1.5.5;RESULTS;701
10.5.2.4.1.5.6;DISCUSSION;701
10.5.2.4.1.5.7;ACKNOWLEDGMENT;703
10.5.2.4.1.5.8;REFERENCES;703
10.5.2.4.2;B.5.2.4.2. B-Cells and Hairy Cell Leukemia;704
10.5.2.4.2.1;CHAPTER
148. INCREASED SENSITIVITY OF DETECTION OF HOMOGENEOUS IMMUNOGLOBULINS IN MURINE B-CELL PROLIFERATIVE DISORDERS WITH SPECIAL EMPHASIS ON THE IgA ISOTYPE;704
10.5.2.4.2.1.1;ABSTRACT;704
10.5.2.4.2.1.2;KEYWORDS;704
10.5.2.4.2.1.3;INTRODUCTION;704
10.5.2.4.2.1.4;MATERIALS AND METHODS;704
10.5.2.4.2.1.5;RESULTS;705
10.5.2.4.2.1.6;DISCUSSION;705
10.5.2.4.2.1.7;ACKNOWLEDGEMENTS;707
10.5.2.4.2.1.8;REFERENCES;707
10.5.2.4.2.2;CHAPTER
149. BETA2'MICROGLOBULIN IN HAIRY CELL LEUKEMIA. STUDY IN 49 PATIENTS. EFFECTS OF SPLENECTOMY;708
10.5.2.4.2.2.1;ABSTRACT;708
10.5.2.4.2.2.2;KEYWORDS;708
10.5.2.4.2.2.3;INTRODUCTION;708
10.5.2.4.2.2.4;METHODS OF
INVESTIGATION;708
10.5.2.4.2.2.5;RESULTS AND DISCUSSON;709
10.5.2.4.2.2.6;REFERENCES;711
10.5.2.4.2.3;CHAPTER
150. IDIOTYPE RESCUE FROM HAIRY CELL LEUKEMIA BY SOMATIC CELL HYBRIDIZATION;712
10.5.2.4.2.3.1;ABSTRACT;712
10.5.2.4.2.3.2;KEYWORDS;712
10.5.2.4.2.3.3;INTRODUCTION;712
10.5.2.4.2.3.4;MATERIALS AND METHODS;713
10.5.2.4.2.3.5;RESULTS AND DISCUSSION;713
10.5.2.4.2.3.6;REFERENCES;715
10.5.2.4.3;B.5.2.4.3. T-CeUs;716
10.5.2.4.3.1;CHAPTER 151. NEOPTERIN, AN INDICATOR OF T-CELL ACTIVATION, IN MONITORING
NEOPLASIAS;716
10.5.2.4.3.1.1;ABSTRACT;716
10.5.2.4.3.1.2;KEYWORDS;716
10.5.2.4.3.1.3;INTRODUCTION;716
10.5.2.4.3.1.4;RESULTS;717
10.5.2.4.3.1.5;CONCLUSIONS;719
10.5.2.4.3.1.6;REFERENCES;719
10.5.2.4.3.2;CHAPTER
152. THE EFFECT OF LOW DOSES OF PREDNISOLONE ON T-CELL SUBSETS IN RHEUMATOID ARTHRITIS;720
10.5.2.4.3.2.1;ABSTRACT;720
10.5.2.4.3.2.2;KEYWORDS;720
10.5.2.4.3.2.3;INTRODUCTION;720
10.5.2.4.3.2.4;MATERIAL AND METHODS;720
10.5.2.4.3.2.5;RESULTS AND DISCUSSION;722
10.5.2.4.3.2.6;CONCLUSION;723
10.5.2.4.3.2.7;REFERENCES;723
10.5.2.4.4;B.5.2.4.4. Chronic Lymphoid Leukemia;724
10.5.2.4.4.1;CHAPTER
153. RELEASE OF PLATELET-ACTIVATING FACTOR FROM HUMAN LEUKAEMIC CELL LINES;724
10.5.2.4.4.1.1;INTRODUCTION;724
10.5.2.4.4.1.2;CELLULAR ORIGIN OF HUMAN PAF;724
10.5.2.4.4.1.3;RELEASE OF PAF FROM HUMAN LEUKAEMIC LYMPHOID CELL LINES;725
10.5.2.4.4.1.4;CONCLUSION;726
10.5.2.4.4.1.5;REFERENCES;726
10.5.2.4.4.2;CHAPTER
154. PLASMA CYCLIC NUCLEOTIDE LEVELS IN EXPERIMENTAL LEUKAEMIA AND COLORECTAL CANCER;728
10.5.2.4.4.2.1;ABSTRACT;728
10.5.2.4.4.2.2;KEYWORDS;728
10.5.2.4.4.2.3;INTRODUCTION;728
10.5.2.4.4.2.4;MATERIALS AND METHODS;728
10.5.2.4.4.2.5;RESULTS;729
10.5.2.4.4.2.6;DISCUSSION;731
10.5.2.4.4.2.7;REFERENCES;731
10.5.2.4.4.3;CHAPTER
155. PLASMA FIBRONECTIN IN HAEMATOLOGICAL DISORDERS;732
10.5.2.4.4.3.1;ABSTRACT;732
10.5.2.4.4.3.2;KEYWORDS;732
10.5.2.4.4.3.3;INTRODUCTION;732
10.5.2.4.4.3.4;METHOD;732
10.5.2.4.4.3.5;RESULTS;734
10.5.2.4.4.3.6;DISCUSSION;734
10.5.2.4.4.3.7;REFERENCES;735
10.5.2.4.4.4;CHAPTER
156. SERUM BETA-2 MICROGLOBULIN IN THE FOLLOW-UP OF CHRONIC LYMPHOCYTIC LEUKEMIA;736
10.5.2.4.4.4.1;ABSTRACT;736
10.5.2.4.4.4.2;INTRODUCTION;736
10.5.2.4.4.4.3;MATERIAL AND METHODS;736
10.5.2.4.4.4.4;ELISA;737
10.5.2.4.4.4.5;RESULTS;737
10.5.2.4.4.4.6;REFERENCES;738
10.5.2.4.4.5;CHAPTER
157. SURFACE FUCOSYL GLYCOPEPTIDES OF HIGH MOLECULAR WEIGHT IN HUMAN LYMPHOCYTIC LEUKEMIC CELLS;740
10.5.2.4.4.5.1;ABSTRACT;740
10.5.2.4.4.5.2;KEYWORDS;740
10.5.2.4.4.5.3;INTRODUCTION;740
10.5.2.4.4.5.4;METHODOLOGY;740
10.5.2.4.4.5.5;RESULTS;741
10.5.2.4.4.5.6;DISCUSSION;743
10.5.2.4.4.5.7;ACKNOWLEDGEMENTS;743
10.5.2.4.4.5.8;REFERENCES;743
10.5.2.4.5;B.5.2.4.5. Myeloid Leukemia;744
10.5.2.4.5.1;CHAPTER 158. CHARACTERIZATION AND MONITORING OF THE MALIGNANT
CELLS IN THE BLASTIC AND CHRONIC PHASE OF CHRONIC MYELOID LEUKEMIA;744
10.5.2.4.5.1.1;ABSTRACT;744
10.5.2.4.5.1.2;KEYWORDS;744
10.5.2.4.5.1.3;INTRODUCTION;744
10.5.2.4.5.1.4;MATERIALS AND METHODS;745
10.5.2.4.5.1.5;RESULTS;745
10.5.2.4.5.1.6;DISCUSSION;747
10.5.2.4.5.1.7;ACKNOWLEDGEMENT;747
10.5.2.4.5.1.8;REFERENCES;747
10.5.2.4.6;B.5.2.4.6. Myeloma;748
10.5.2.4.6.1;CHAPTER
159. SEPARATIONOF LIGHT CHAINS IN MYELOMATOSISBY FAST PROTEIN LIQUID CHROMATOGRAPHYTM;748
10.5.2.4.6.1.1;ABSTRACT;748
10.5.2.4.6.1.2;KEYWORDS;748
10.5.2.4.6.1.3;INTRODUCTION;748
10.5.2.4.6.1.4;MATERIALS AND METHODS;748
10.5.2.4.6.1.5;RESULTS;749
10.5.2.4.6.1.6;CONCLUSIONS;749
10.5.2.4.6.1.7;REFERENCES;751
10.5.2.4.6.2;CHAPTER
160. MULTIPLE MYELOMA ASSESSMENT BY ISOELECTRIC FOCUSING IN PATIENTS WITH APPARENTLY INCREASED BETAGLOBULIN ON CELLULOSE ACETATE ELECTROPHORESIS;752
10.5.2.4.6.2.1;ABSTRACT;752
10.5.2.4.6.2.2;KEYWORDS;752
10.5.2.4.6.2.3;INTRODUCTION;752
10.5.2.4.6.2.4;MATERIALS AND METHODS;752
10.5.2.4.6.2.5;RESULTS;753
10.5.2.4.6.2.6;CONCLUSIONS;754
10.5.2.4.6.2.7;REFERENCES;755
10.5.2.5;B.5.2.5. Various Organs;756
10.5.2.5.1;CHAPTER
161. EXPRESSION OF A HIGH MOLECULAR WEIGHT PROTEIN OF KIDNEY TUBULAR BRUSH BORDER MEMBRANE IN RENAL CARCINOMAS;756
10.5.2.5.1.1;ABSTRACT;756
10.5.2.5.1.2;KEYTORDS;756
10.5.2.5.1.3;INTRODUCTION;756
10.5.2.5.1.4;MATERIALS AND METHODS;757
10.5.2.5.1.5;RESULTS AND DISCUSSION;757
10.5.2.5.1.6;ACKNOWLEDGEMENTS;757
10.5.2.5.1.7;REFERENCES;759
10.5.2.5.2;CHAPTER
162. MODIFICATION OF TUMOR CELL PROLIFERATION AND PEPTIDE HORMONE SECRETION;760
10.5.2.5.2.1;ABSTRACT;760
10.5.2.5.2.2;INTRODUCTION;760
10.5.2.5.2.3;METHODS;760
10.5.2.5.2.4;RESULTS;761
10.5.2.5.2.5;DISCUSSION;763
10.5.2.5.2.6;REFERENCES;763
10.5.2.5.3;CHAPTER
163. TRANSFORMATION'ENHANCING ACTIVITY PRESENT IN THE PLASMA OF CANCER PATIENTS BINDS TO GELATIN;764
10.5.2.5.3.1;ABSTRACT;764
10.5.2.5.3.2;KEYWORDS;764
10.5.2.5.3.3;INTRODUCTION;764
10.5.2.5.3.4;MATERIALS AND METHODS;764
10.5.2.5.3.5;RESULTS AND DISCUSSION;765
10.5.2.5.3.6;ACKNOWLEDGEMENTS;767
10.5.2.5.3.7;REFERENCES;767
10.5.2.5.4;CHAPTER
164. ANTIBODIES AGAINST .-AND Z-DNA

IN PATIENTS WITH SLE;768
10.5.2.5.4.1;KEYWORDS;768
10.5.2.5.4.2;INTRODUCTION;768
10.5.2.5.4.3;jyiATERIALS AND METHODS;768
10.5.2.5.4.4;RESULTS;769
10.5.2.5.4.5;DISCUSSION;770
10.5.2.5.4.6;REFERENCES;771
10.6;..6. Prognosis;772
10.6.1;CHAPTER
165. ELEVATED LEVELS OF ....·

MALIGNIN ANTIBODY ARE

QUANTITATIVELY RELATED TO

LONGER SURVIVAL IN CANCER PATIENTS;772
10.6.1.1;SUMMARY;772
10.6.1.2;INTRODUCTION;772
10.6.1.3;PATIßNTS AND METHODS;773
10.6.1.4;RESULTS;773
10.6.1.5;SURVIVAL STUDY;777
10.6.1.6;DISCUSSION;779
10.6.1.7;REFEllENCEo;779
10.6.2;CHAPTER
166. TUMOR BURDEN AND ITS RELATIONSHIP TO ANTIGEN, SIZE AND COMPOSITION OF IMMUNE COMPLEXES;782
10.6.2.1;ABSTRACT;782
10.6.2.2;KEY WORDS;782
10.6.2.3;INTRODUCTION;782
10.6.2.4;METHODS AND RESULTS;783
10.6.2.5;DISCUSSION AND CONCLUDING REMARKS;784
10.6.2.6;REFERENCES;785
10.6.3;CHAPTER
167. UTILIZATION OF ALPHA-l-ANTITRYPSININ STAGINGOF MALIGNANTDISEASES;786
10.6.3.1;ABSTRACT;786
10.6.3.2;KEYWORDS;786
10.6.3.3;INTRODUCTION;786
10.6.3.4;MATERIAL AND METHODS;786
10.6.3.5;RESULTS;787
10.6.3.6;CONCLUSION;787
10.6.3.7;REFERENCES;788
10.7;..7. Treatment;790
10.7.1;CHAPTER
168. ATTEMPTS OF TREATMENT OF HEPATOMA WITH ANTIBODY TO ALPHA-FETOPROTEIN;790
10.7.1.1;ABSTRACT;790
10.7.1.2;INTRODUCTION;790
10.7.1.3;MATERIALS AND METHODS;790
10.7.1.4;RESULTS;791
10.7.1.5;DISCUSSION;797
10.7.1.6;REFERENCES;798
11;SECTION C: Monoclonal Antibodies;800
11.1;C.1. Drug Targeting;802
11.1.1;CHAPTER
169. USE OF MONOCLONAL ANTIBODYINTACT RICIN CONJUGATES IN EXPERIMENTAL ALLOGENEIC BONE MARROW TRANSPLANTATION;802
11.1.1.1;ABSTRACT;802
11.1.1.2;KEYWORDS;802
11.1.1.3;INTRODUCTION;802
11.1.1.4;MATERIALS AND METHODS;803
11.1.1.5;RESULTS AND DISCUSSION;804
11.1.1.6;ACKNOWLEDGEMENT;806
11.1.1.7;REFERENCES;807
11.1.2;CHAPTER
170. APPLICATION OF MONOCLONAL ANTIBODY 79IT/36 FOR RADIOIMMUNODETECTION OF HUMAN TUMOURS AND FOR TARGETING CYTOTOXIC DRUGS;808
11.1.2.1;ABSTRACT;808
11.1.2.2;KEYWORDS;808
11.1.2.3;INTRODUCTION;808
11.1.2.4;CONCLUSIONS;813
11.1.2.5;ACKNOWLEDGEMENTS;814
11.1.2.6;REFERENCES;814
11.1.3;CHAPTER
171. SUPPRESSION OF GROWTH OF A HUMAN COLORECTAL TUMOUR IN NUDE MICE BY VINDESINE-MONOCLONAL ANTI-CEA CONJUGATES;816
11.1.3.1;ABSTRACT;816
11.1.3.2;KEYWORDS;816
11.1.3.3;INTRODUCTION;816
11.1.3.4;MATERIALS AND METHODS;816
11.1.3.5;RESULTS;817
11.1.3.6;DISCUSSION;818
11.1.3.7;REFERENCES;819
11.1.4;CHAPTER
172. MONOCLONAL ANTI-CEA ANTIBODIES FOR TARGETING CHLORAMBUCIL TO HUMAN COLON CARCINOMA CELLS IN VITRO;820
11.1.4.1;ABSTRACT;820
11.1.4.2;INTRODUCTION;820
11.1.4.3;MATERIALS AND METHODS;820
11.1.4.4;PREPARATION OF CHLORAMBUCIL-ANTI-CEA CONJUGATES.;821
11.1.4.5;ALKYLATING ACTIVITY ASSAY.;821
11.1.4.6;INHIBITION OF COLONY FORMATION.;821
11.1.4.7;INHIBITION OF THYMIDINE INCORPORATION.;821
11.1.4.8;RESULTS;821
11.1.4.9;PHARMACOLOGICAL ACTIVITY OF THE CONJUGATE.;822
11.1.4.10;CONCLUSIONS.;823
11.1.4.11;REFERENCES.;823
11.1.5;CHAPTER
173. DRUG TARGETING WITH MONOCLONAL ANTIBODY FOR HUMAN HEPATOMAS;824
11.1.5.1;ABSTRACT;824
11.1.5.2;KEY WORDS;824
11.1.5.3;INTRODUCTION;824
11.1.5.4;MATERIALS AND METHODS;825
11.1.5.5;RESULTS;825
11.1.5.6;DISCUSSION;827
11.1.5.7;REFERENCES;827
11.1.6;CHAPTER
174. LOCALISATION OF A MONOCLONAL ANTIBODY LABELLED WITH ASTATINE-2I1 TO A HUMAN HETEROGRAFT TUMOUR IN NUDE MICE;828
11.1.6.1;ABSTRACT;828
11.1.6.2;KEYWORDS;828
11.1.6.3;INTRODUCTION;828
11.1.6.4;METHODS;829
11.1.6.5;RESULTS;829
11.1.6.6;DISCUSSION;830
11.1.6.7;REFERENCES;831
11.1.7;CHAPTER
175. PREPARATIONAND EXPERIMENTATION OF ANANTIDIGITALINMONOCLONAL ANTIBODY:INTERESTIN HUMAN TREATMENT;832
11.1.7.1;ABSTRACT;832
11.1.7.2;KEY-WORDS;832
11.1.7.3;INTRODUCTION;832
11.1.7.4;MATERIEL AND METHODS;833
11.1.7.5;MAIN CARÁCTERISTICS;834
11.1.7.6;APPLICATIONS;835
11.1.7.7;REFERENCES;836
11.2;C.2.Immunohistochemistry;838
11.2.1;CHAPTER
176. IMMUNOHISTOLOGICAL DISTRIBUTION OF THE ANTIGENIC DETERMINANTSRECOGNIZEDBY MONOCLONAL ANTIBODIES REACTING WITH CARCINOEMBRYONIC ANTIGEN;838
11.2.1.1;ABSTRACT;838
11.2.1.2;KEY WORDS;838
11.2.1.3;INTRODUCTION;838
11.2.1.4;MATERIALS AND METHODS;838
11.2.1.5;RESULTS;839
11.2.1.6;DISCUSSION;841
11.2.1.7;ACKNOWLEDGEMENTS;841
11.2.1.8;REFERENCES;841
11.2.2;CHAPTER
177. ANTIGENIC HETEROGENEITY OF HUMAN MAMMARY CARCINOMA CELLS DEFINED BY MONOCLONAL ANTIBODIES;842
11.2.2.1;ABSTRACT;842
11.2.2.2;KEYWORDS;842
11.2.2.3;INTRODUCTION;842
11.2.2.4;RESULTS;842
11.2.2.5;REFERENCES;845
11.2.3;CHAPTER
178. DIFFERENTIAL REACTIVITY OF HUMAN MACROPHAGE SUBSETS TO MPS-SPECIFIC MONOCLONAL ANTIBODIES KLMl-4;846
11.2.3.1;ABSTRACT;846
11.2.3.2;KEYWORDS;846
11.2.3.3;INTRODUCTION;846
11.2.3.4;MATERIAL AND METHODS;846
11.2.3.5;RESULTS;847
11.2.3.6;DISCUSSION;848
11.2.3.7;ACKNOWLEDGEMENT;848
11.2.3.8;REFERENCES;848
11.2.4;CHAPTER
179. IMMUNOENZYMATIC IDENTIFICATION OF MALIGNANT CELLS IN SEROUS EFFUSIONS USING MONOCLONAL ANTIBODIES;850
11.2.4.1;ABSTRACT;850
11.2.4.2;KEYWORDS;850
11.2.4.3;INTRODUCTION;850
11.2.4.4;METHODS;851
11.2.4.5;RESULTS;851
11.2.4.6;LEGENDS TO FIGURES;852
11.2.4.7;CONCLUSIONS;853
11.2.4.8;ACKNOWLEDGEMENTS;853
11.2.4.9;REFERENCES;853
11.2.5;CHAPTER
180. USE OF MONOCLONAL ANTIBODIES FOR THE HISTOLOGICAL LOCALIZATION OF MELANOMA ASSOCIATED ANTIGENS ON FRESH TUMOR MATERIAL;854
11.2.5.1;ABSTRACT;854
11.2.5.2;INTRODUCTION;854
11.2.5.3;MATERIAL AND METHODS;855
11.2.5.4;RESULTS;856
11.2.5.5;DISCUSSION;857
11.2.5.6;REFERENCES;858
11.2.6;CHAPTER
181. AN IMMUNOHISTOLOGICAL STUDY OF SKIN TUMOURS;860
11.2.6.1;ABSTRACT;860
11.2.6.2;KEYWORDS;860
11.2.6.3;INTRODUCTION;860
11.2.6.4;MATERIALS AND METHODS;860
11.2.6.5;RESULTS AND DISCUSSION;861
11.2.6.6;CONCLUSIONS;863
11.2.6.7;ACKNOWLEDGEMENTS;863
11.2.6.8;REFERENCE;863
11.2.7;CHAPTER
182. USE OF MONOCLONAL ANTIBODIES TO KERATIN IN HUMAN TUMOR DIAGNOSIS;864
11.2.7.1;ABSTRACT;864
11.2.7.2;INTRODUCTION;864
11.2.7.3;MATERIALS AND METHODS;865
11.2.7.4;RESULTS AND DISCUSSION;865
11.2.7.5;REFERENCES;867
11.2.8;CHAPTER
183. IDENTIFICATION OF AA-TYPE AMYLOID IN TISSUE SECTIONS USING MONOCLONAL ANTIBODIES;868
11.2.8.1;ABSTRACT;868
11.2.8.2;KEYWORDS;868
11.2.8.3;INTRODUCTION;868
11.2.8.4;MATERIAL AND METHODS;869
11.2.8.5;RESULTS;869
11.2.8.6;DISCUSSION;869
11.2.8.7;ACKNOWLEDGEMENTS;871
11.2.8.8;REFERENCES;871
11.2.9;CHAPTER
184. CAN WE PREDICT THE BIOLOGICAL BEHAVIOUR OF CARCINOMA OF THE BREAST USING MONOCLONAL ANTIBODIES AND AUTO-ANTIBODIES?;872
11.2.9.1;INTRODUCTION;872
11.2.9.2;MATERIALS AND METHODS;872
11.2.9.3;RESULTS AND DISCUSSION;873
11.2.9.4;ACKNOWLEDGMENTS;876
11.2.9.5;REFERENCES;876
11.2.10;CHAPTER
185. MONOCLONALANTIBODIESAGAINST RENALADENOCARCINOMA:EVALUATION OF EPITOPESIN COMMON WITH PLACENTALAND FETAL TISSUE;878
11.2.10.1;INTRODUCTION;878
11.2.10.2;METHODS;878
11.2.10.3;RESULTS AND DISCUSSION;879
11.2.10.4;ACKNOWLEDGEMENT;881
11.2.10.5;REFERENCES;881
11.2.11;CHAPTER

186. PRODUCTION AND ROLE OF MONOCLONAL ANTIBODIES IN TRANSITIONAL CELL CARCINOMA OF THE BLADDER;882
11.2.11.1;ABSTRACT;882
11.2.11.2;KEYWORDS;882
11.2.11.3;INTRODUCTION;882
11.2.11.4;METHOD;883
11.2.11.5;RESULTS;883
11.2.11.6;SUMMARY;884
11.2.11.7;ACKNOWLEDGEMENTS;885
11.2.11.8;REFERENCES;885
11.2.12;CHAPTER
187. IMMUNOHISTOLOGICAL DIAGNOSIS OF BRAIN TUMOURS USING MONOCLONAL ANTIBODIES;886
11.2.12.1;ABSTRACT;886
11.2.12.2;KEYWORDS;886
11.2.12.3;INTRODUCTION;886
11.2.12.4;MATERIALS AND METHODS;886
11.2.12.5;RESULTS;888
11.2.12.6;ILLUSTRATIVE CASES;888
11.2.12.7;DISCUSSION;889
11.2.12.8;ACKNOWLEDGEMENTS;889
11.2.12.9;REFERENCES;890
11.3;C.3.Lymphocytes;892
11.3.1;CHAPTER
188. PHENOTYPESOF HUMAN NATIVE NATURALKILLER (NK) CELLSAND MLCACTIVATEDNK- LIKE CELLS;892
11.3.1.1;ABSTRACT;892
11.3.1.2;KEYWORDS;892
11.3.1.3;INTRODUCTION;892
11.3.1.4;RESULTS AND DISCUSSION;893
11.3.1.5;REFERENCES;895
11.3.2;CHAPTER 189. CHARACTERISATION OF A SUBSET OF OKT8+, OKTIO+, OKT3-, HNK-l'
CELLS WITH NK ACTIVITY IN CORD BLOOD LYMPHOCYTES;896
11.3.2.1;ABSTRACT;896
11.3.2.2;KEYWORDS;896
11.3.2.3;INTRODUCTION;896
11.3.2.4;MATERIALS AND METHODS;896
11.3.2.5;RESULTS AND DISCUSSION;898
11.3.2.6;REFERENCES;899
11.3.3;CHAPTER

90. PRODUCTION AND

CHARACTERIZATION OF MURINE

MONOCLONAL ANTIBODIES AGAINST

HUMAN . CELL SURFACE

DETERMINANTS;902
11.3.3.1;ABSTRACT;902
11.3.3.2;KEYWORDS;902
11.3.3.3;INTRODUCTION;902
11.3.3.4;MATERIALS AND METHODS;902
11.3.3.5;RESULTS;903
11.3.3.6;DISCUSSION;905
11.3.3.7;ACKNOWLEDGEMENT;905
11.3.3.8;REFERENCES;905
11.3.4;CHAPTER
191. CHARACTERIZATION OF A NEW

HGPRT(-) HUMAN . LYMPHOID CELL

LINE;906
11.3.4.1;ABSTRACT;906
11.3.4.2;KEYWORDS;906
11.3.4.3;INTRODUCTION;906
11.3.4.4;MATERIALS and METHODS;906
11.3.4.5;RESULTS;907
11.3.4.6;CONCLUSION;908
11.3.4.7;ACKNOWLEDGEMENT;908
11.3.4.8;REFERENCES;908
11.3.5;CHAPTER
192. ANALYSIS WITH MONOCLONAL ANTIBODIES OF LYMPHOCYTE MEMBRANE FUNCTIONS IN AGEING;910
11.3.5.1;ABSTRACT;910
11.3.5.2;KEYWORDS;910
11.3.5.3;INTRODUCTION;910
11.3.5.4;MATERIALS AND METHODS;910
11.3.5.5;RESULTS AND DISCUSSION;913
11.3.5.6;ACKNOWLEDGEMENTS;913
11.3.5.7;REFERENCES;913
11.3.6;CHAPTER
193. DETECTION OF B-LYMPHOCYTES IN PERIPHERAL BLOOD AND OTHER TISSUES BY IMMUNOHISTOCHEMICAL METHODS USING MONOCLONAL, la-LIKE ANTIGEN SPECIFIC, ANTIBODIES;914
11.3.6.1;ABSTRACT;914
11.3.6.2;KEYWORDS;914
11.3.6.3;INTRODUCTION;914
11.3.6.4;MATERIALS AND METHODS;914
11.3.6.5;RESULTS;915
11.3.6.6;DISCUSSION;916
11.3.6.7;ACKNOWLEDGEMENT;917
11.3.6.8;REFERENCES;917
11.3.7;CHAPTER

194. DYNAMICS IN LYMPHOCYTE SUBSETS WITH MONOCLONAL ANTIBODIES IN KIDNEY TRANSPLANTATION;918
11.3.7.1;ABSTRACT;918
11.3.7.2;KEYWORDS;918
11.3.7.3;INTRODUCTION;918
11.3.7.4;MATERIAL AND METHODS;918
11.3.7.5;RESULTS;919
11.3.7.6;DISCUSSION;920
11.3.7.7;ACKNOWLEDGEMENT;921
11.3.7.8;REFERENCES;921
11.3.8;CHAPTER
195. T-CELL SUBPOPULATIONS IN PERIPHERAL BLOOD AND SYNOVIAL FLUID IN RHEUMATIC DISEASES;922
11.3.8.1;ABSTRACT;922
11.3.8.2;KEYWORDS;922
11.3.8.3;INTRODUCTION;922
11.3.8.4;SUBJECTS AND METHODS;922
11.3.8.5;RESULTS;923
11.3.8.6;DISCUSSION;924
11.3.8.7;REFERENCES;925
11.3.9;CHAPTER
196. MONOCLONAL ANTIBODIES RAISED

AGAINST DIAMINOPEPTIDASE IV

OCCURRING IN HUMAN . LYMPHOCYTES

AND MYOFIBROBLASTS;926
11.3.9.1;ABSTRACT;926
11.3.9.2;KEYWORDS;926
11.3.9.3;INTRODUCTION;926
11.3.9.4;MATERIAL AND METHODS;926
11.3.9.5;RESULTS;927
11.3.9.6;DISCUSSION;927
11.3.9.7;REFERENCES;927
11.3.10;CHAPTER
197. THE USE OF MONOCLONAL ANTIBODIES TO DETECT LYMPHOCYTE T-CELL SUBPOPULATIONS WITHIN THE HUMAN TRANSPLANTED HEART;928
11.3.10.1;ABSTRACT;928
11.3.10.2;KEYWORDS.;928
11.3.10.3;INTRODUCTION.;928
11.3.10.4;MATERIALS AND METHODS.;929
11.3.10.5;RESULTS;929
11.3.10.6;DISCUSSION;930
11.3.10.7;CONCLUSIONS;930
11.3.10.8;REFERENCES;930
11.3.11;CHAPTER 198. A HAEMOPOIETIC PRECURSOR CELL

ANTIGEN SHARED BY BOTH . AND .

CELLS;932
11.3.11.1;ABSTRACT;932
11.3.11.2;INTRODUCTION;932
11.3.11.3;MATERIALS AND METHODS;933
11.3.11.4;RESULTS AND CONCLUSION;933
11.3.11.5;ACKNOWLEDGMENT;935
11.3.11.6;REFERENCES;935
11.4;C.4. CEA;936
11.4.1;CHAPTER 199. DIAGNOSTIC VALUE OF THE MONOCLONAL ANTIBODIES TO ANTIGENIC DETERMINANTS ON CEA MOLECULE;936
11.4.1.1;ABSTRACT;936
11.4.1.2;KEY WORDS;936
11.4.1.3;INTRODUCTION;936
11.4.1.4;MATERIALS AND METHODS;936
11.4.1.5;RESULTS AND DISCUSSION;938
11.4.1.6;ACKNOWLEDGEMENTS;939
11.4.1.7;REFERENCES;940
11.4.2;CHAPTER 200. DETERMINATION OF ANTIGENIC DETERMINANTS ON CEA MOLECULES OF DIFFERENT TUMOR ORIGIN BY MONOCLONAL ANTIBODIES;942
11.4.2.1;ABSTRACT;942
11.4.2.2;KEYWORDS;942
11.4.2.3;INTRODUCTION;942
11.4.2.4;MATERIALS AND METHODS;943
11.4.2.5;RESULTS AND DISCUSSION;943
11.4.2.6;REFERENCES;944
11.4.3;CHAPTER
201. CHARACTERIZATION OF FOUR MONOCLONAL ANTIBODIES DIRECTED AGAINST CARCINO EMBRYONIC ANTIGEN;946
11.4.3.1;INTRODUCTION;946
11.4.3.2;MATERIALS AND METHODS;946
11.4.3.3;RESULTS AND DISCUSSION;948
11.4.3.4;CONCLUSION;948
11.4.3.5;REFERENCES;948
11.4.4;CHAPTER 202. AFFINITY PURIFICATION OF CEA USING AN IMMOBILISED MONOCLONAL ANTLCEA ANTIBODY;950
11.4.4.1;ABSTRACT;950
11.4.4.2;INTRODUCTION;950
11.4.4.3;mTERIALS AND METHODS;950
11.4.4.4;RESULTS AND DISCUSSION;951
11.4.4.5;ACKNOWLEDGEMENTS;952
11.4.4.6;REFERENCES;952
11.4.5;CHAPTER 203. CLASSIFICATION OF ANTI-CEA MONOCLONAL ANTIBODIES;954
11.4.5.1;ABSTRACT;954
11.4.5.2;KEYWORDS;954
11.4.5.3;INTRODUCTION;954
11.4.5.4;MATERIALS AND METHODS;955
11.4.5.5;RESULTS AND DISCUSSION;955
11.4.5.6;REFERENCES;957
11.4.6;CHAPTER 204. DETERMINATION OF EPITOPE SPECIFICITIES OF MONOCLONAL ANTIBODIES AGAINST CEA: USE THE AVIDIN-BIOTIN SYSTEM;958
11.4.6.1;ABSTRACT;958
11.4.6.2;KEYTORDS;958
11.4.6.3;INTRODUCTION;958
11.4.6.4;MATERIALS AND METHODS;958
11.4.6.5;RESULTS AND DISCUSSION;959
11.4.6.6;ACKNOWLEDGEMENT;960
11.4.6.7;REFERENCES;961
11.4.7;CHAPTER 205. DIFFERENCES AMOUNG INDIVIDUAL CEA PREPARATIONS AND CARCINOMAS OF DIFFERENT ORIGIN AS DETECTED BY MONOCLONAL ANTLCEA ANTIBODIES;962
11.4.7.1;ABSTRACT;962
11.4.7.2;KEYWORDS;962
11.4.7.3;INTRODUCTION;962
11.4.7.4;MATERIALS AND METHODS;962
11.4.7.5;RESULTS AND DISCUSSION;963
11.4.7.6;REFERENCES;965
11.4.8;CHAPTER 206. .......-PATHOLOGICAL ANALYSIS

OF HUMAN TUMORS WITH 3 ANTI

CARCINO-EMBRYONIC ANTIGEN

MONOCLONAL ANTIBODIES;966
11.4.8.1;ABSTRACT;966
11.4.8.2;KEY WORDS;966
11.4.8.3;MATERIEL AND METHODS;966
11.4.8.4;RESULTS;967
11.4.8.5;REFERENCES;969
11.4.9;CHAPTER 207. DETECTION OF CARCINOEMBRYONIC ANTIGEN IN CANCER SERUM BY TWO-DIMENSIONAL GEL ELECTROPHORESIS;970
11.4.9.1;ABSTRACT;970
11.4.9.2;KEYWORDS;970
11.4.9.3;INTRODUCTION;970
11.4.9.4;METHODS;971
11.4.9.5;RESULTS;971
11.4.9.6;DISCUSSION;972
11.4.9.7;ACKNOWLEDGEMENTS;973
11.4.9.8;REFERENCES;973
11.4.10;CHAPTER 208. PROGNOSTIC SIGNIFICANCE OF CEA IN GASTROINTESTINAL CANCER;974
11.4.10.1;ABSTRACT;974
11.4.10.2;KEYWORDS;974
11.4.10.3;INTRODUCTION;974
11.4.10.4;RESULTS AND DISCUSSION;974
11.4.10.5;ACKNOWLEDGEMENT;977
11.4.10.6;REFERENCES;977
11.4.11;CHAPTER 209. IN VIVO CORRELATION OF CIRCULATING CEA AND TUMOR VOLUME IN PATIENTS WITH SOLITARY METASTASES;978
11.4.11.1;ABSTRACT;978
11.4.11.2;KEYWORDS;978
11.4.11.3;INTRODUCTION;978
11.4.11.4;MATERIAL and METHOD;978
11.4.11.5;RESULTS and DISCUSSION;979
11.4.11.6;CONCLUSIONS;981
11.4.11.7;REFERENCES;981
11.4.12;CHAPTER 210. COMPARISON OF SERUM AND TISSUE CEA LEVELS IN LUNG CANCER;982
11.4.12.1;ABSTRACT;982
11.4.12.2;KEYWORDS;982
11.4.12.3;INTRODUCTION;982
11.4.12.4;MATERIAL AND METHODS;983
11.4.12.5;RESULTS;983
11.4.12.6;DISCUSSION;985
11.4.12.7;ACKNOWLEDGEMENT;985
11.4.12.8;REFERENCES;985
11.4.13;CHAPTER 211. PRELIMINARY RESULTS OF PHOSPHOHEXOSE ISOMERASE AND CARCINOEMBRYONIC ANTIGEN IN PRIMARY LUNG CANCER;986
11.4.13.1;ABSTRACT;986
11.4.13.2;KEYWORDS;986
11.4.13.3;INTRODUCTION;986
11.4.13.4;MATERIALS AND METHODS;986
11.4.13.5;RESULTS;987
11.4.13.6;HISTOLOGICAL CATEGORIES;987
11.4.13.7;INDISTINCT ELEVATION OF PHI AND/OR CEA;988
11.4.13.8;PRELIMINARY FOLLOW UP EVALUATION;988
11.4.13.9;PROGNOSTIC VALUE OF PHI AND CEA;988
11.4.13.10;METASTASES;989
11.4.13.11;DISCUSSION;989
11.4.13.12;ACKNOWLEDGEMENTS;989
11.4.13.13;REFERENCES;989
11.4.14;CHAPTER 212. ACUTE CHANGES OF SERUM CEA IN PATIENTS UNDERGOING SURGERY FOR A COLORECTAL CANCER;990
11.4.14.1;INTRODUCTION;990
11.4.14.2;MATERIALS AND METHODS;990
11.4.14.3;RESULTS;991
11.4.14.4;DISCUSSION;991
11.4.14.5;REFERENCES;991
11.4.15;CHAPTER 213. TISSUE FERRITIN AND CEA CONCENTRATIONS IN BREAST CANCERS. COMPARISON WITH SERUM LEVELS AND IMMUNOHISTOCHEMISTRY RESULTS;992
11.4.15.1;KEY WORDS;992
11.4.15.2;INTRODUCTION;992
11.4.15.3;MATERIALS AND METHODS;992
11.4.15.4;RESULTS;993
11.4.15.5;DISCUSSION;994
11.4.15.6;BIBLIOGRAPHIE;995
11.4.16;CHAPTER 214. EVALUATION OF BETA GLUCURONIDASE, CARCINOEMBRYONIC ANTIGEN, FERRITIN AND POLYAMINES AS TUMOR MARKERS OF CENTRAL NERVOUS SYSTEM;996
11.4.16.1;ABSTRACT;996
11.4.16.2;KEY WORDS;996
11.4.16.3;INTRODUCTION;996
11.4.16.4;MATERIAL AND METHODS;996
11.4.16.5;RESULTS;997
11.4.16.6;DISCUSSION;999
11.4.16.7;ACKNOWLEDGEMENT;999
11.4.16.8;REFERENCES;999
11.4.17;CHAPTER 215. ULTRASTRUCTURAL LOCALIZATION

OF CARCINOEMBRYONIC ANTIGEN IN

A CONTINUOUS HUMAN TUMOUR

LINE (LS 174 .) IN RELATION TO

MORPHOMETRIC INVESTIGATIONS;1000
11.4.17.1;ABSTRACT;1000
11.4.17.2;KEYWORDS;1000
11.4.17.3;INTRODUCTION;1000
11.4.17.4;ACKNOWLEDGEMENTS;1003
11.4.17.5;REFERENCES;1003
11.5;C.5. Various Antigens;1004
11.5.1;CHAPTER 216. IN VIVO DISTRIBUTION OF ANTI-HUMAN MELANOMA MONOCLONAL ANTIBODIES;1004
11.5.1.1;INTRODUCTION;1004
11.5.1.2;MATERIALS AND METHODS;1004
11.5.1.3;RESULTS;1005
11.5.1.4;DISCUSSION;1008
11.5.1.5;REFERENCES;1009
11.5.2;CHAPTER 217. MONOCLONAL ANTIBODIES AGAINST NON SPECIFIC CROSS-REACTING ANTIGEN;1010
11.5.2.1;REFERENCES;1012
11.5.3;CHAPTER 218. CHARACTERIZATIONOF MONOCLONAL ANTIBODIES TO BOVINE INSULIN;1014
11.5.3.1;ABSTRACT;1014
11.5.3.2;KEYWORDS;1014
11.5.3.3;INTRODUCTION;1014
11.5.3.4;RESULTS AND DISCUSSION;1015
11.5.3.5;ACKNOWLEDGEMENTS;1017
11.5.3.6;REFERENCES;1017
11.5.4;CHAPTER 219. MONOCLONAL ANTIBODIES DIRECTED AGAINST HUMAN LOW DENSITY LIPOPROTEIN AND THEIR CHARACTERIZATION BY THE IMMUNODOT TECHNIQUE;1018
11.5.4.1;ABSTRACT;1018
11.5.4.2;KEYWORDS;1018
11.5.4.3;INTRODUCTION;1018
11.5.4.4;MATERIALS AND METHODS;1018
11.5.4.5;CHARACTERIZATION OF THE MONOCLONAL ANTIBODIES;1020
11.5.4.6;DISCUSSION;1020
11.5.4.7;ACKNOWLEDGMENTS;1021
11.5.4.8;REFERENCES;1021
11.5.5;CHAPTER 220. MONOCLONAL ANTIBODY SRB5B1 RECOGNIZES A GANGLIOSIDE ANTIGEN SHARED BY HUMAN MELANOMA AND COLON CARCINOMA CELL LINES;1022
11.5.5.1;ABSTRACT;1022
11.5.5.2;KEYWORDS;1022
11.5.5.3;INTRODUCTION;1022
11.5.5.4;MATERIALS AND METHODS;1023
11.5.5.5;RESULTS AND DISCUSSION;1023
11.5.5.6;ACKNOWLEDGMENTS;1025
11.5.5.7;REFERENCES;1025
11.5.6;CHAPTER 221. MONOCLONAL ANTIBODIES REVEAL SACCHARIDE STRUCTURES AS DIFFERENTIATION AND TUMOUR ASSOCIATED ANTIGENS OF HAEMATOPOEITIC AND EPITHELIAL CELLS OF MAN AND MOUSE;1026
11.5.6.1;ABSTRACT;1026
11.5.6.2;KEYWORDS;1026
11.5.6.3;INTRODUCTION;1026
11.5.6.4;RESULTS AND DISCUSSION;1026
11.5.6.5;CONCLUSION;1028
11.5.6.6;REFERENCES;1028
11.5.7;CHAPTER 222. PERICELLULAR GLYCOPROTEINS ORGANIZATION IN TUMORIGENIC AND NON TUMORIGENIC HUMAN CELL HYBRIDS;1030
11.5.7.1;ABSTRACT;1030
11.5.7.2;KEYWORDS;1030
11.5.7.3;INTRODUCTION;1030
11.5.7.4;RESULTS AND DISCUSSION;1030
11.5.7.5;ACKNOWLEDGEMENTS;1033
11.5.7.6;REFERENCES;1033
11.5.8;CHAPTER 223. IMMUNOCHEMICAL ANALYSIS OF NORMAL AND NEOPLASTIC HUMAN MAMMARY ANTIGENS USING MONOCLONAL ANTIBODY LICR-LONM18 AND PEANUT AGGLUTININ;1034
11.5.8.1;ABSTRACT;1034
11.5.8.2;KEY WORDS;1034
11.5.8.3;INTRODUCTION;1034
11.5.8.4;MATERIALS AND METHODS;1034
11.5.8.5;DISCUSSION;1037
11.5.8.6;REFERENCES;1037
11.5.9;CHAPTER 224. INTERCHANGE OF ALLOSPECIFIC MHC CLASS 1 PEPTIDE CHAINS WITH XENOSPECIFIC ß2MICROGLOBULIN AND ITS IMPLICATIONS FOR GENETIC RESTRICTION;1038
11.5.9.1;ABSTRACT;1038
11.5.9.2;KEYWORDS;1038
11.5.9.3;INTRODUCTION;1038
11.5.9.4;RESULTS AND DISCUSSIONS;1038
11.5.9.5;CONCLUSION;1039
11.5.9.6;ACKIffllxFLSDGEMENTS;1041
11.5.9.7;REFERENCES;1041
11.5.10;CHAPTER 225. SWEATGLANDSAND SALIVARY GLANDS AS MODEL SYSTEM FOR THE CHARACTERIZATION OF MONOCLONAL ANTIBODIES AGAINSTDIFFERENTIATION ANTIGENS
OF THE HUMAN MAMMARY GLAND;1042
11.5.10.1;ABSTRACT;1042
11.5.10.2;KEYWORDS;1042
11.5.10.3;INTRODUCTION;1042
11.5.10.4;MATERIAL AND METHODS;1043
11.5.10.5;RESULTS;1043
11.5.10.6;LOCALIZATION OF ANTIGENS ON SALIVARY GLANDS;1043
11.5.10.7;DISCUSSION;1045
11.5.10.8;REFERENCES;1045
11.5.11;CHAPTER
226. MONOCLONAL ANTIBODIES AGAINST HUMAN MILKFAT GLOBULE MEMBRANES USEFUL IN CARCINOMA RESEARCH;1046
11.5.11.1;ABSTRACT;1046
11.5.11.2;KEYWORDS;1046
11.5.11.3;INTRODUCTION;1046
11.5.11.4;MATERIALS AND METHODS;1046
11.5.11.5;RESULTS;1047
11.5.11.6;DISCUSSION;1049
11.5.11.7;REFERENCES;1049
11.5.12;CHAPTER 227. MONOCLONAL ANTIBODIES TO HUMAN MAMMARY CARCINOMA CELLS;1050
11.5.12.1;ABSTRACT;1050
11.5.12.2;KEYWORDS;1050
11.5.12.3;INTRODUCTION;1050
11.5.12.4;MATERIAL AND METHODS;1051
11.5.12.5;RESULTS AND DISCUSSION;1052
11.5.12.6;REFERENCES;1053
11.5.13;CHAPTER 228. REACTIONS OF MONOCLONAL ANTIBODIES AGAINST HUMAN MILK FAT GLOBULE MEMBRANES WITH EMBRYONAL TISSUE;1054
11.5.13.1;ABSTRACT;1054
11.5.13.2;KEYWORDS;1054
11.5.13.3;INTRODUCTION;1054
11.5.13.4;MATERIALS AND METHODS;1054
11.5.13.5;RESULTS;1056
11.5.13.6;DISCUSSION;1057
11.5.13.7;ACKNOWLEDGEMENT AND REFERENCES;1057
11.6;C.6. Clinical Assays;1058
11.6.1;CHAPTER 229. MONOCLONAL ANTIBODIES AND A STREPTAVIDIN-BIOTIN SYSTEM USED IN AN ENZYME IMMUNOASSA Y FOR CARCINOEMBRYONIC ANTIGEN;1058
11.6.1.1;ABSTRACT;1058
11.6.1.2;Keywords;1058
11.6.1.3;INTRODUCTION;1058
11.6.1.4;MATERIALS AND METHODS;1059
11.6.1.5;RESULTS;1060
11.6.1.6;DISCUSSION;1063
11.6.1.7;REFERENCES;1063
11.6.2;CHAPTER 230. TRIPLE ANTIBODY PRECIPITATION FOR RADIOIMMUNOASSAYS EMPLOYING MONOCLONAL ANTIBODIES, EXEMPLIFIED BY AN ASSAY FOR hCG;1064
11.6.2.1;ABSTRACT;1064
11.6.2.2;INTRODUCTION;1064
11.6.2.3;ASSAY PROCEDURE;1064
11.6.2.4;ASSAY RESULTS;1065
11.6.2.5;DISCUSSION;1065
11.6.2.6;REFERENCES;1066
11.6.3;CHAPTER 231. SELECTION AND CHARACTERIZATION OF MONOCLONAL ANTIBODIES DIRECTED AGAINST HUMAN CHORIONIC GONADOTROPIN;1068
11.6.3.1;ABSTRACT;1068
11.6.3.2;KEYWORDS;1068
11.6.3.3;INTRODUCTION;1068
11.6.3.4;MATERIAL AND METHODS;1068
11.6.3.5;RESULTS AND DISCUSSION;1069
11.6.3.6;REFERENCES;1071
11.6.4;CHAPTER 232. A CRITICAL EVALUATIONOF A TWO-SITE IMMUNORADIOMETRIC ASSAY OF HUMAN PROLACTIN, USING MONOCLONAL ANTIBODIES;1072
11.6.4.1;ABSTRACT;1072
11.6.4.2;KEYWORDS;1072
11.6.4.3;INTRODUCTION;1072
11.6.4.4;MATERIALS AND METHODS;1072
11.6.4.5;RESULTS AND DISCUSSION;1073
11.6.4.6;CONCLUSION;1075
11.6.4.7;REFERENCES;1075
11.6.5;CHAPTER 233. MONOCLONAL ANTIBODIES AGAINST HUMAN CHORIONIC SOMATOMAMMOTROPIN: PRODUCTION, IMMUNOLOGICAL CHARACTERIZATION AND IMMUNOHISTOCHEMICAL USE IN PATHOLOGY;1076
11.6.5.1;ABSTRACT;1076
11.6.5.2;KEY WORDS;1076
11.6.5.3;INTRODUCTION;1076
11.6.5.4;MATERIALS AND METHODS;1077
11.6.5.5;RESULTS;1077
11.6.5.6;DISCUSSION;1078
11.6.5.7;REFERENCES;1079
11.6.6;CHAPTER 234. MONOCLONAL ANTIBODIES AS TOOLS FOR KIDNEY DAMAGE DIAGNOSIS;1080
11.6.6.1;ABSTRACT;1080
11.6.6.2;KEYWORDS;1080
11.6.6.3;INTRODUCTION;1080
11.6.6.4;MATERIAL AND METHODS;1081
11.6.6.5;RESULTS;1081
11.6.6.6;CONCLUSIONS;1083
11.6.6.7;ACKNOWLEDGEMENTS;1083
11.6.6.8;REFERENCES;1083
11.6.7;CHAPTER 235. POLYCLONAL OR MONOCLONAL ANTIBODIES IN AN AFP ASSA Y;1084
11.6.7.1;INTRODUCTION;1084
11.6.7.2;MATERIALS AND METHODS;1084
11.6.7.3;RESULTS;1085
11.6.7.4;DISCUSSION;1087
11.6.7.5;REFERENCES;1087
11.6.8;CHAPTER 236. MONOCLONAL ANTIBODIES AGAINST HUMAN BLOOD GROUP ANTIGENS;1088
11.6.8.1;ABSTRACT;1088
11.6.8.2;KEYWORDS;1088
11.6.8.3;INTRODUCTION;1088
11.6.8.4;HYBRIDOMAS SECRETING MONOCLONAL ANTIBODIES AGAINST BLOOD GROUP ANTIGENS;1088
11.6.8.6;CONCLUSION;1090
11.6.8.7;REFERENCES;1091
11.6.9;CHAPTER 237. MONOCLONAL ANTIBODIES AGAINST SOME BLOOD GROUP ANTIGENS;1092
11.6.9.1;ABSTRACT;1092
11.6.9.2;KEY WORDS;1092
11.6.9.3;INTRODUCTION;1092
11.6.9.4;MATERIALS;1093
11.6.9.5;METHODS;1093
11.6.9.6;RESULTS AND DISCUSSION;1094
11.6.9.7;REFERENCES;1095
11.6.10;CHAPTER 238. USE OF MONOCLONAL ANTIBODIES FOR PRECIPITIN REACTIONS;1096
11.6.10.1;ABSTRACT;1096
11.6.10.2;KEYWORDS;1096
11.6.10.3;INTRODUCTION;1096
11.6.10.4;MATERIALS AND METHODS;1097
11.6.10.5;RESULTS AND DISCUSSION;1097
11.6.10.6;ACKNOWLEDGEMENT;1099
11.6.10.7;REFERENCES;1099
11.6.11;CHAPTER 239. DIFFERENCES BETWEEN THE PLACENTAL AND THE TESTICULAR PLACENTAL'LIKE ALKALINE PHOSPHATASE AS DETECTED BY MONOCLONAL ANTIBODIES;1100
11.6.11.1;ABSTRACT;1100
11.6.11.2;KEYWORDS;1100
11.6.11.3;INTRODUCTION;1100
11.6.11.4;MATERIALS AND METHODS;1101
11.6.11.5;RESULTS AND DISCUSSION;1101
11.6.11.6;ACKNOWLEDGEMENTS;1103
11.6.11.7;REFERENCES;1103
11.6.12;CHAPTER 240. USE OF MONOCLONAL IgG SUBCLASS ANTIBODIES FOR CHARACTERIZATION OF ANTIBODIES FROM SERA OF HBs VACCINATED INDIVIDUALS;1104
11.6.12.1;ABSTRACT;1104
11.6.12.2;KEY WORDS;1104
11.6.12.3;INTRODUCTION;1104
11.6.12.4;MATERIAL AND METHODS;1104
11.6.12.5;RESULTS;1105
11.6.12.6;ACKNOWLEDGEMENTS;1107
11.6.12.7;REFERENCES;1107
11.6.13;CHAPTER 241. DIFFERENT FINE SPECIFICITIES OF HUMAN MONOCLONAL ANTLGd COLD AGGLUTININS;1108
11.6.13.1;ABSTRACT;1108
11.6.13.2;KEYWORDS;1108
11.6.13.3;INTRODUCTION;1108
11.6.13.4;MATERIALS AND METHODS;1109
11.6.13.5;RESULTS AND CONCLUSIONS;1109
11.6.13.6;ACKNOWLEDGEMENT;1111
11.6.13.7;REFERENCES;1111
11.6.14;CHAPTER 242. A NEW SCREENING TECHNIQUE FOR IgM MONOMERS;1112
11.6.14.1;ABSTRACT;1112
11.6.14.2;KEYWORDS;1112
11.6.14.3;INTRODUCTION;1112
11.6.14.4;MATERIAL AND METHOD;1113
11.6.14.5;RESULTS;1113
11.6.14.6;CONCLUSION;1114
11.6.14.7;REFERENCES;1115
11.6.15;CHAPTER 243. THE USE OF ENZYME-LINKED SECOND ANTIBODIES IN IMMUNODIFFUSION TECHNIQUES ON CELLULOSE ACETATE MEMBRANES;1116
11.6.15.1;ABSTRACT;1116
11.6.15.2;KEYWORDS;1116
11.6.15.3;INTRODUCTION;1116
11.6.15.4;METHODS;1116
11.6.15.5;RESULTS;1117
11.6.15.6;DISCUSSION;1119
11.6.15.7;ACKNOWLEDGEMENT;1119
11.6.15.8;REFERENCES;1119
11.6.16;CHAPTER 244. MONOCLONALANTIBODIESAGAINST BLOOD GROUP ANTIGENS;1120
11.6.16.1;ABSTRACT;1120
11.6.16.2;INTRODUCTION;1120
11.6.16.3;MATERIAL AND METHODS;1121
11.6.16.4;RESULTS;1122
11.6.16.5;CONCLUSIONS;1124
11.6.16.6;REFERENCES;1124
11.6.17;CHAPTER 245. A LECTIN CELL BINDING ASSAY;1126
11.6.17.1;ABSTRACT;1126
11.6.17.2;KEYWORDS;1126
11.6.17.3;INTRODUCTION;1126
11.6.17.4;METHODS;1126
11.6.17.5;RESULTS AND DISCUSSION;1127
11.6.17.6;LEGEND TO FIGURE 1;1128
11.6.17.7;ACKNOWLEDGEMENTS;1129
11.6.17.8;REFERENCES;1129
12;AUTHOR INDEX;1130
13;SUBJECT INDEX;1138